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Abstract: Pyridoxal 5’-phosphat (PLP)-abhängige Enzyme katalysieren vielfältige Umwandlungen von
Aminosäuren, wie Transaminierung, ￿-Decarboxylierung und Razemisierung sowie ￿/￿- Eliminierungs- und
Substitutionsreaktionen. Vitamin B6-abhängige Enzyme spielen eine zentrale Rolle im Aminosäure- und
Aminmetabolismus und sind interessante Zielobjekte für Medikamente, um auf spezifische, zu pathologis-
chen Zuständen führende Prozesse einzuwirken. Hemmstoffe, welche der Struktur des Übergangszustands
entsprechen, binden mit hoher Affinität an ihre Zielenzyme. Unter Anwendung dieses Prinzips wurde
in dieser Doktorarbeit eine Strategie erarbeitet, um spezifische, intrazellulär wirkende Inhibitoren für
bestimmte PLP-abhängige Enzyme zu entwickeln. Die PLP-abhängige Ornithindecarboxylase (ODC) ist
ein Schlüssenenzym der Polyaminsynthese und wurde als erstes Zielobjekt ausgewählt. ODC ist in vie-
len Tumorzellen überexprimiert und deren Hemmung ist daher von grossem therapeutischem Interesse.
Im ersten Teil der Doktorarbeit werden Design und Synthese eines solchen ODC-Inhibitors vorgestellt.
Eine genaue Analyse der 3-D-Struktur von hODC offenbarte eine zusätzliche hydrophobe Tasche, welche
die ￿-Aminogruppe des Substrats Ornithins umhüllt. Molekülmodellierung mit einem BOC-geschützten
Pyridoxyl-Ornithin-Konjugat (POB) in der aktiven Stelle der hODC deuteten auf eine starke Wechsel-
wirkung des Enzyms mit der BOC- Gruppe hin. Das synthetisierte und gereinigte POB hemmte die
Aktivität neu induzierter ODC in verschiedenen Tumorzellen. Das Ausmass der Hemmung der ODC-
Aktivität korrelierte mit der zeitabhängigen Hemmung des Zellwachstums. Menschliche nicht-cancerogene
glatte Muskelzellen der Aorta wurden nicht gehemmt. Die Proliferationshemmung von Tumorzellen
durch POB war beträchtlich wirksamer als die von ￿-DL-Difluoromethylornithine (DFMO), des medi-
zinisch am häufigsten verwendeten irreversiblen ODC-Inhibitors. Um die hemmende Wirkung dieser Art
von intrazellulärem ODC-Inhibitoren zu verbessern, wurden im zweiten Teil der Doktorarbeit die struk-
turellen Anforderungen für das Binden und Hemmen von hODC und für die Zellproliferation genauer
untersucht. Strukturell unterschiedliche Enzym-Substrat-Analoge wurden entwickelt, synthetisiert und
auf Hemmwirkung getestet. Von 23 untersuchten Konjugaten zeigten zwei, nämlich Phosphorpyridoxyl-
und Pyridoxyl-Tryptophanmethylester (pPTME, PTME), eine signifikant grössere Zellproliferationshem-
mung als POB und insbesondere eine viel grössere als DFMO. Alle aktiven Verbindungen besitzen ein
hydrophobes Seitenkettenfragment und ein polyaminähnliches Motiv. Wie sich aus Untersuchungen mit-
tels molekularem Modellieren vermuten liess, haben pPTME und PTME eine grössere Bindungsaffinität
zu ODC als POB und hemmen die intrazelluläre ODC-Aktivität auch stärker. Zusätzlich induzieren
diese drei Verbindungen, wie bereits von Polyaminanalogen bekannt, die Aktivitäten der Polyaminoxi-
dase und der Spermin/Spermidin-N1-Acetyltransferase bis zu 250 % bzw. 780 %. Beide Enzyme sind
im katabolen Polyaminstoffwechsel wirksam. Die duale Wirkung dieser Verbindungen, d.h. die Hem-
mung der ODC und die Induktion der katabolischen Enzyme, beeinflusst die intrazellulären Polyam-
inpools und könnte der Grund sein für den im Vergleich zu DFMO viel besseren Hemmeffekt auf die
Zellproliferation. Histamin, ein biogenes Amin mit wichtigen biologischen Funktionen, wird durch die
Decarboxylierung von Histidin mittels Histidin-Decarboxylase (HDC), einem PLP- abhängigen Enzym,
gebildet. HDC ist demzufolge ein wichtiges Zielenzym für Hemmstoffe, um die Histaminproduktion in
bestimmten pathologischen Zuständen zu verringern. Die Entwicklung neuer Inhibitoren der hHDC und
die Aufklärung von deren strukturellen Voraussetzungen ist eine grosse Herausforderung, da die 3D-
Struktur der HDC von Säugetieren noch immer unbekannt ist. Im letzten Teil der Dissertation wurden
potentiell membrandurchlässige Pyridoxylsubstratkonjugate entwickelt, synthetisiert und als Inhibitoren
der hHDC getestet. Ferner wurde ein Modell der aktiven Stelle der hHDC entworfen, das mit den ex-
perimentellen Daten kompatibel ist. Von den 9 mit menschlichen Mastzellen getesteten strukturellen
Varianten hemmte das Pyridoxyl-Histidin-Methylesterkonjugat (PHME) die HDC am stärksten, was da-
rauf schliessen lässt, dass die Bindungsstelle von hHDC keine andere Gruppe als die Imidazol-Seitenkette
von Histidin akzeptiert. PHME vermochte vor allem die induzierte neu synthetisierte HDC zu hemmen
und zeigte auch Hemmwirkung in Zellextrakten. Das vorgeschlagene Modell des aktiven Zentrums der
hHDC, welches Phosphopyridoxyl-Histidin enthält, erklärte die Bindungsspezifizität von HDC für ihr
Substrat und erhellt die Struktur-Aktivitätsbeziehung der entwickelten und untersuchten Verbindungen.
Zusammenfassend zeigen die Ergebnisse, dass die Anwendung strukturell verschiedener Verbindungen
zur Abklärung der Bindungsanforderungen der Zielproteine ein effizienter Weg zur Entwicklung neuer
Inhibitoren von PLP-abhängiger Enzyme ist. ODC-Inhibitoren, wie sie hier vorgestellt wurden, können
von Zellen aufgenommen werden und das Zellwachstum klinisch wichtiger bösartiger Tumorzelllinien, wie
Gliomazellen, effizient hemmen. Pyridoxal 5’-phosphate (PLP)-dependent enzymes catalyze manifold
transformations of amino acids such as transamination, ￿-decarboxylation, and racemization, as well as ￿-
or ￿- elimination and replacement reactions. Vitamin B6-dependent enzymes play a central role in amine
and amino acid metabolism and are interesting targets for drugs to intervene in specific processes that
lead to pathological states. As transition-state-based inhibitors bind with high affinity to their target
enzymes, a strategy was explored to develop inhibitors on the basis of mimics of a transition-state in-
termediate of PLP-dependent enzymic reactions. The PLP-dependent ornithine decarboxylase (ODC) is
the key enzyme in polyamine synthesis and was chosen as the first target. ODC is overexpressed in many
tumor cells and thus a potential drug target. The thesis reports the design and synthesis of an analog
of covalent coenzyme-substrate adducts as a novel precursor inhibitor of ODC. Structural analysis of the
crystal structure of hODC disclosed a hydrophobic pocket adjacent to the ￿- amino group of its substrate
ornithine. Molecular modeling showed favorable interactions of a BOC-protected pyridoxyl-ornithine
conjugate, termed POB, in the active site of hODC. The synthesized and purified POB at the concen-
tration of 100 µM completely inhibited the activity of newly induced ODC in glioma LN229 and COS7
cells. In correlation with the inhibition of intracellular ODC activity, a time-dependent inhibition of cell
growth was also observed in various tumor cell lines, but not in non-tumorigenic human aortic smooth
muscle cells. POB was much more efficient in inhibiting proliferation of several types of tumor cells than
￿-DL-difluoromethylornithine (DFMO), the most widely used irreversible inhibitor of ODC. In the second
part of the thesis, the structural requirements for binding to and inhibiting hODC and for inhibition of
cell proliferation were elucidated in more detail to improve the inhibitory effect of this kind of inhibitors
of intracellular hODC. Structurally diverse enzyme- substrate mimics were designed, synthesized and
tested for their inhibitory potential. Out of 23 conjugates, phosphopyridoxyl- and pyridoxyl-tryptophan
methyl ester (pPTME, PTME) showed a significantly more potent cell proliferation inhibition of glioma
cells than POB and particularly more than DFMO. All the active compounds possess a hydrophobic
side chain and polyamine motif (-NH-(CHX)4-NH-). As predicted from the molecular modeling results,
pPTME and PTME have an improved binding affinity for ODC in comparison to POB and strongly
inhibited the intracellular ODC activity of glioma cells. Additionally, these three compounds induce,
as polyamine analogs do, the activity of the enzymes of polyamine catabolism, polyamine oxidase and
spermine/spermidine N1-acetyltransferase, up to 250% and 780%, respectively. The dual mode of these
compounds in cells, i.e. inhibition of ODC and induction of polyamine catabolic enzymes, influences the
intracellular polyamine pools and might be the cause for their inhibitory effect on cell proliferation that
compares favorably with that of DFMO. Histamine, a biogenic amine with important biological func-
tions, for example in gastric acid secretion and allergic reactions, is produced from histidine by histidine
decarboxylase (HDC), a PLP-dependent enzyme. HDC is thus a potential target to attenuate histamine
production in certain pathological states. Targeting mammalian HDC with novel inhibitors and eluci-
dating the structural basis of their specificity for HDC are particularly challenging tasks, because the 3D
structure of mammalian HDC is still unknown. In the last part of my dissertation, potentially membrane-
permeable pyridoxyl-substrate conjugates were designed, synthesized and tested as inhibitors for human
HDC and an active site of hHDC was modeled that is compatible with the experimental data. The most
potent inhibitory compound among 9 tested structural variants was the pyridoxyl-histidine methyl ester
conjugate (PHME), indicating that the binding site of hHDC does not tolerate other groups than the
imidazole side chain of histidine. PHME inhibited induced HDC in human HMC-1 cells and proved also
inhibitory in cell extracts. The proposed model of hHDC, containing phosphopyridoxyl- histidine in the
active site, explains the binding specificity of HDC towards its substrate and the structure-activity rela-
tionship of the investigated compounds. In conclusion, analogs of covalent coenzyme-substrate adducts
and their structural variations provide promising lead compounds for the development of inhibitors for
PLP- dependent enzymes such as ODC and HDC. ODC inhibitors of the kind presented in this thesis
seem to be efficient agents for preventing proliferation of clinically interesting malignant tumor cell lines,
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ABBREVIATIONS 
 
APAO Acetyl polyamine oxidase 
AZ Antizyme 
BOC Tert-butoxycarbonyl 
BOL BOC-protected lysine methyl ester 
BOM BOC-protected ornithine methyl ester 
DDC Dopa decarboxylase 
DENspm N1, N11- di(ethyl)- norspermine 
DFMO α-DL-difluoromethylornithine 
ERE Estrogen response elements 
GBM                   Glioblastoma multiforme 
HAT Histone acetyltransferases  
HDAC Histone deacetylases 
HDC Histidine decarboxylase 
HMC Human mast cell 
HME Histidine methyl ester 
LCMB                  Lung cancer metastasizing cells in brain 
NO Nitric oxide 
NOS Nitric oxide synthase 
ODC Ornithine decarboxylase 
PAO Polyamine oxidase 
PHME Pyridoxyl-histidine methyl ester 
PLP Pyridoxal 5’-phosphate 
POB                   N-(4’-pyridoxyl)-ornithine-BOC 
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PT Polyamine transporter 
PUT Putrescine 
SMO Spermine oxidase 
SPD Spermidine 
SPM Spermine 
SSAT Spermine/spermidine N1- acetyltransferase 
TPA 12-O-Tetradecanoylphorbol-13-acetate  
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Zusammenfassung 
 
Pyridoxal 5’-phosphat (PLP)-abhängige Enzyme katalysieren vielfältige Umwandlungen von 
Aminosäuren, wie Transaminierung, α-Decarboxylierung und Razemisierung sowie β/γ-
Eliminierungs- und Substitutionsreaktionen. Vitamin B6-abhängige Enzyme spielen eine 
zentrale Rolle im Aminosäure- und Aminmetabolismus und sind interessante Zielobjekte für 
Medikamente, um auf spezifische, zu pathologischen Zuständen führende Prozesse 
einzuwirken. Hemmstoffe, welche der Struktur des Übergangszustands entsprechen, binden 
mit hoher Affinität an ihre Zielenzyme. Unter Anwendung dieses Prinzips wurde in dieser 
Doktorarbeit eine Strategie erarbeitet, um spezifische, intrazellulär wirkende Inhibitoren für 
bestimmte PLP-abhängige Enzyme zu entwickeln. 
 
     Die PLP-abhängige Ornithindecarboxylase (ODC) ist ein Schlüssenenzym der 
Polyaminsynthese und wurde als erstes Zielobjekt ausgewählt. ODC ist in vielen Tumorzellen 
überexprimiert und deren Hemmung ist daher von grossem therapeutischem Interesse. Im 
ersten Teil der Doktorarbeit werden Design und Synthese eines solchen ODC-Inhibitors 
vorgestellt. Eine genaue Analyse der 3-D-Struktur von hODC offenbarte eine zusätzliche 
hydrophobe Tasche, welche die ε-Aminogruppe des Substrats Ornithins umhüllt. 
Molekülmodellierung mit einem BOC-geschützten Pyridoxyl-Ornithin-Konjugat (POB) in der 
aktiven Stelle der hODC deuteten auf eine starke Wechselwirkung des Enzyms mit der BOC-
Gruppe hin. Das synthetisierte und gereinigte POB hemmte die Aktivität neu induzierter ODC 
in verschiedenen Tumorzellen. Das Ausmass der Hemmung der ODC-Aktivität korrelierte mit 
der zeitabhängigen Hemmung des Zellwachstums. Menschliche nicht-cancerogene glatte 
Muskelzellen der Aorta wurden nicht gehemmt. Die Proliferationshemmung von Tumorzellen 
durch POB war beträchtlich wirksamer als die von α-DL-Difluoromethylornithine (DFMO), 
des medizinisch am häufigsten verwendeten irreversiblen ODC-Inhibitors. 
     Um die hemmende Wirkung dieser Art von intrazellulärem ODC-Inhibitoren zu verbessern, 
wurden im zweiten Teil der Doktorarbeit die strukturellen Anforderungen für das Binden und 
Hemmen von hODC und für die Zellproliferation genauer untersucht. Strukturell 
unterschiedliche Enzym-Substrat-Analoge wurden entwickelt, synthetisiert und auf 
Hemmwirkung getestet. Von 23 untersuchten Konjugaten zeigten zwei, nämlich 
Phosphorpyridoxyl- und Pyridoxyl-Tryptophanmethylester (pPTME, PTME), eine signifikant 
grössere Zellproliferationshemmung als POB und insbesondere eine viel grössere als DFMO. 
Alle aktiven Verbindungen besitzen ein hydrophobes Seitenkettenfragment und ein 
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polyaminähnliches Motiv. Wie sich aus Untersuchungen mittels molekularem Modellieren 
vermuten liess, haben pPTME und PTME eine grössere Bindungsaffinität zu ODC als POB 
und hemmen die intrazelluläre ODC-Aktivität auch stärker. Zusätzlich induzieren diese drei 
Verbindungen, wie bereits von Polyaminanalogen bekannt, die Aktivitäten der 
Polyaminoxidase und der Spermin/Spermidin-N1-Acetyltransferase bis zu 250 % bzw. 780 %. 
Beide Enzyme sind im katabolen Polyaminstoffwechsel wirksam. Die duale Wirkung dieser 
Verbindungen, d.h. die Hemmung der ODC und die Induktion der katabolischen Enzyme, 
beeinflusst die intrazellulären Polyaminpools und könnte der Grund sein für den im Vergleich 
zu DFMO viel besseren Hemmeffekt auf die Zellproliferation. 
 
      Histamin, ein biogenes Amin mit wichtigen biologischen Funktionen, wird durch die 
Decarboxylierung von Histidin mittels Histidin-Decarboxylase (HDC), einem PLP-
abhängigen Enzym, gebildet. HDC ist demzufolge ein wichtiges Zielenzym für Hemmstoffe, 
um die Histaminproduktion in bestimmten pathologischen Zuständen zu verringern. Die 
Entwicklung neuer Inhibitoren der hHDC und die Aufklärung von deren strukturellen 
Voraussetzungen ist eine grosse Herausforderung, da die 3D-Struktur der HDC von 
Säugetieren noch immer unbekannt ist. Im letzten Teil der Dissertation wurden potentiell 
membrandurchlässige Pyridoxylsubstratkonjugate entwickelt, synthetisiert und als Inhibitoren 
der hHDC getestet. Ferner wurde ein Modell der aktiven Stelle der hHDC entworfen, das mit 
den experimentellen Daten kompatibel ist. Von den 9 mit menschlichen Mastzellen getesteten 
strukturellen Varianten hemmte das Pyridoxyl-Histidin-Methylesterkonjugat (PHME) die 
HDC am stärksten, was darauf schliessen lässt, dass die Bindungsstelle von hHDC keine 
andere Gruppe als die Imidazol-Seitenkette von Histidin akzeptiert. PHME vermochte vor 
allem die induzierte neu synthetisierte HDC zu hemmen und zeigte auch Hemmwirkung in 
Zellextrakten. Das vorgeschlagene Modell des aktiven Zentrums der hHDC, welches 
Phosphopyridoxyl-Histidin enthält, erklärte die Bindungsspezifizität von HDC für ihr Substrat 
und erhellt die Struktur-Aktivitätsbeziehung der entwickelten und untersuchten Verbindungen. 
 
      Zusammenfassend zeigen die Ergebnisse, dass die Anwendung strukturell verschiedener 
Verbindungen zur Abklärung der Bindungsanforderungen der Zielproteine ein effizienter Weg 
zur Entwicklung neuer Inhibitoren von PLP-abhängiger Enzyme ist. ODC-Inhibitoren, wie sie 
hier vorgestellt wurden, können von Zellen aufgenommen werden und das Zellwachstum 
klinisch wichtiger bösartiger Tumorzelllinien, wie Gliomazellen, effizient hemmen. 
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SUMMARY 
 
Pyridoxal 5’-phosphate (PLP)-dependent enzymes catalyze manifold transformations of 
amino acids such as transamination, α-decarboxylation, and racemization, as well as β- or γ-
elimination and replacement reactions. Vitamin B6-dependent enzymes play a central role in 
amine and amino acid metabolism and are interesting targets for drugs to intervene in specific 
processes that lead to pathological states. As transition-state-based inhibitors bind with high 
affinity to their target enzymes, a strategy was explored to develop inhibitors on the basis of 
mimics of a transition-state intermediate of PLP-dependent enzymic reactions.  
     The PLP-dependent ornithine decarboxylase (ODC) is the key enzyme in polyamine 
synthesis and was chosen as the first target. ODC is overexpressed in many tumor cells and 
thus a potential drug target. The thesis reports the design and synthesis of an analog of 
covalent coenzyme-substrate adducts as a novel precursor inhibitor of ODC. Structural 
analysis of the crystal structure of hODC disclosed a hydrophobic pocket adjacent to the ε-
amino group of its substrate ornithine. Molecular modeling showed favorable interactions of a 
BOC-protected pyridoxyl-ornithine conjugate, termed POB, in the active site of hODC. The 
synthesized and purified POB at the concentration of 100 µM completely inhibited the 
activity of newly induced ODC in glioma LN229 and COS7 cells. In correlation with the 
inhibition of intracellular ODC activity, a time-dependent inhibition of cell growth was also 
observed in various tumor cell lines, but not in non-tumorigenic human aortic smooth muscle 
cells. POB was much more efficient in inhibiting proliferation of several types of tumor cells 
than α-DL-difluoromethylornithine (DFMO), the most widely used irreversible inhibitor of 
ODC.  
 In the second part of the thesis, the structural requirements for binding to and inhibiting 
hODC and for inhibition of cell proliferation were elucidated in more detail to improve the 
inhibitory effect of this kind of inhibitors of intracellular hODC. Structurally diverse enzyme-
substrate mimics were designed, synthesized and tested for their inhibitory potential. Out of 
23 conjugates, phosphopyridoxyl- and pyridoxyl-tryptophan methyl ester (pPTME, PTME) 
showed a significantly more potent cell proliferation inhibition of glioma cells than POB and 
particularly more than DFMO. All the active compounds possess a hydrophobic side chain 
and polyamine motif (-NH-(CHX)4-NH-). As predicted from the molecular modeling results, 
pPTME and PTME have an improved binding affinity for ODC in comparison to POB and 
strongly inhibited the intracellular ODC activity of glioma cells. Additionally, these three 
compounds induce, as polyamine analogs do, the activity of the enzymes of polyamine 
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catabolism, polyamine oxidase and spermine/spermidine N1-acetyltransferase, up to 250% 
and 780%, respectively. The dual mode of these compounds in cells, i.e. inhibition of ODC 
and induction of polyamine catabolic enzymes, influences the intracellular polyamine pools 
and might be the cause for their inhibitory effect on cell proliferation that compares favorably 
with that of DFMO. 
     
    Histamine, a biogenic amine with important biological functions, for example in gastric 
acid secretion and allergic reactions, is produced from histidine by histidine decarboxylase 
(HDC), a PLP-dependent enzyme. HDC is thus a potential target to attenuate histamine 
production in certain pathological states. Targeting mammalian HDC with novel inhibitors 
and elucidating the structural basis of their specificity for HDC are particularly challenging 
tasks, because the 3D structure of mammalian HDC is still unknown. In the last part of my 
dissertation, potentially membrane-permeable pyridoxyl-substrate conjugates were designed, 
synthesized and tested as inhibitors for human HDC and an active site of hHDC was modeled 
that is compatible with the experimental data. The most potent inhibitory compound among 9 
tested structural variants was the pyridoxyl-histidine methyl ester conjugate (PHME), 
indicating that the binding site of hHDC does not tolerate other groups than the imidazole side 
chain of histidine. PHME inhibited induced HDC in human HMC-1 cells and proved also 
inhibitory in cell extracts. The proposed model of hHDC, containing phosphopyridoxyl-
histidine in the active site, explains the binding specificity of HDC towards its substrate and 
the structure-activity relationship of the investigated compounds. 
     
 
In conclusion, analogs of covalent coenzyme-substrate adducts and their structural 
variations provide promising lead compounds for the development of inhibitors for PLP-
dependent enzymes such as ODC and HDC. ODC inhibitors of the kind presented in this 
thesis seem to be efficient agents for preventing proliferation of clinically interesting 
malignant tumor cell lines, such as gliomas. 
 
General introduction                                                   9                
 
1. General introduction 
 
1.1 Pyridoxal 5’-phosphate dependent enzymes as therapeutic targets 
 
Pyridoxal 5’-phosphate (PLP)-dependent enzymes widely exist in both prokaryotes 
(1.5% of all genes) and eukaryotes, and have important biological functions (Amadasi 
et al, 2007). PLP-dependent enzymes are involved in many cellular processes, 
including the biosynthesis of amino acids, amino acid-derived metabolites and amino 
sugars (Eliot & Kirsch, 2004). They catalyze various types of reactions, featured by 
the heterolytic cleavage of sigma bonds at the substrate Cα atom (Fig. 1). These 
enzymes can be classified according to the reactions proceeding through: i) α 
-decarboxylation (Fig. 1, (b)); ii) proton elimination, e.g. racemization and 
transamination (Fig. 1(a)); and iii) elimination of the side chain of amino acids, e.g. 
aldolic cleavage (Fig. 1(c)) as well as ß, γ elimination and substitution. The external 
aldimine (Fig. 1), a Schiff base of PLP with the α-amino group of the amino acid 
substrate, is the common intermediate in all transformation of amino acid catalyzed 
by PLP-dependent enzymes (Christen & Mehta, 2001). All PLP-dependent enzymes 
have a Lys residue in the active site which forms the internal Schiff base with the 
cofactor PLP, and specific protein motifs to tightly bind the cofactor.  
 
Fig. 1 Reactions catalyzed by PLP-dependent enzymes.  
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  The common mechanistic features of PLP-dependent enzymes are not historical 
traits passed on from a common ancestor enzyme but rather reflect evolutionary or 
chemical necessities (Mehta & Christen, 2000). According to the amino acid 
sequences, supported by comparisons of the available three-dimensional crystal 
structures, vitamin B6-dependent enzymes can be classified into four independent 
evolutionary lineages of homologous proteins, i.e. the α family with aspartate 
aminotransferase as the prototype enzyme, the ß family with tryptophan synthase b as 
the prototype enzyme, the D-alanine aminotransferase family and the alanine 
racemase family (Mehta & Christen, 2000). 
   PLP-dependent enzymes are key enzymes in many metabolic pathways, such as 
ornithine decarboxylase in polyamine metabolism; glutamate decarboxylase, aromatic 
amino acid or dopa decarboxylase and histidine decarboxylase in the biosynthesis of 
neurotransmitters and biogenic amines such as dopamine, serotonin and histamine; 
GABA transaminase in the degradation of γ-aminobutyric acid 
(http://www.biocarta.com and (Duffy et al, 2004)); and serine palmitoyltransferase in 
sphingolipid metabolism (Hanada, 2003). These enzymes are targets for treatment of 
diseases, such as sleeping sickness, cancer, epilepsy and Parkinson's disease (Duffy et 
al, 2004; Rabasseda, 1999). Several inhibitors, that target these enzymes are already 
on the market as clinical drugs. Gamma-Vinyl-GABA (Vigabatrin) an inhibitor of 
GABA aminotransferase is used as epileptic drug; carbidopa, an inhibitor of dopa 
decarboxylase in Parkinson’s disease; α-DL-difluoromethylornitine (DFMO), an 
irreversible inhibitor of ornithine decarboxylase (ODC) against sleeping sickness, and 
D-cycloserine, an inhibitor of alanine racemase to treat tuberculosis (Casero & 
Marton, 2007)). All of them are substrate analogs (Fig. 2).  
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Fig. 2 Chemical structures of commercial drugs targeting PLP-dependent 
enzymes. 
 
 
1.2 Polyamine pathway 
 
1.2.1 Polyamines 
Polyamines, namely spermine (SPM), spermidine (SPD) and putrescine (PUT), are 
multi-charged biogenic amines. They are essential for eukaryotic and in most cases 
also for prokaryotic cell growth and differentiation (Casero & Marton, 2007). 
Polyamines were originally thought to be DNA-binding agents, allowing DNA 
condensation and controlling DNA conformations (Childs et al, 2003; Seiler, 2003).  
Polyamines are required for the proliferation of both normal and neoplastic cell (Li et 
al, 2007). The metabolism of polyamines (Fig. 3) comprises polyamine biosynthesis 
catalyzed by ornithine decarboxylase and spermine/spermidine synthase, polyamine 
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catabolism catalyzed by spermine/spermidine N1-acetyltransferase (SSAT) and 
polyamine oxidase (PAO) as well as polyamine uptake and secretion by a polyamine 
transport system (PT) (Casero & Marton, 2007). All these enzymes and PT (red, Fig3.) 
are regarded as potential anti-cancer targets. 
 
 
Fig. 3 The metabolic pathway of polyamines in cells. Red, enzymes; Green, 
inhibitors. 
 
1.2.2 Human ornithine decarboxylase 
Human ornithine decarboxylase (ODC), a PLP-dependent enzyme, catalyzes the first 
and rate–limiting step in polyamine biosynthesis by converting ornithine to putrescine 
(Fig. 3). ODC is a highly inducible and short-lived enzyme with a half life of 20 ~ 60 
min (Seiler, 2003). Transcription, translation and degradation of ODC are highly 
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regulated by different mechanisms in cells (Origanti & Shantz, 2007; Pegg, 2006). 
Odc is the first target of the oncogene c-myc and the increased activity of the 
Myc/Max transcription complex increases the expression of ODC mRNA (Wagner et 
al, 1993). Many other regulatory factors have also been shown to stimulate the 
synthesis of ODC mRNA due to a promoter region in the Odc gene that contains 
multiple sequences such as a cAMP response element, CAAT and LSF motifs, AP-1 
and AP-2 sites, GC-rich Sp1 binding sites and a TATA box, allowing responses to 
hormones, growth factors, and tumor promoters (Bercovich & Kahana, 2004; Zhao & 
Butler, 2001). Numerous studies have indicated that translation of ODC mRNA is 
reduced by excessive polyamines (Pegg, 2006). However, the mechanism underlying 
this effect is not clear. Antizyme, a protein inhibitor of mammalian ODC, is a negative 
regulator of intracellular polyamine levels. The expression of antizyme can be 
induced by polyamines through a ribosomes shift (+1) mechanism (Childs et al, 2003). 
The antizyme guides ODC into 26S proteasomes for degradation without the 
involvement of ubiquitin (Murakami et al, 1992).  
  ODC is considered as a potential anti-cancer target (Casero et al, 2005; Seiler, 
2003). ODC is frequently upregulated in proliferating cells and has been implicated as 
an oncogene in multiple types of tumors. The amount of ODC is closely related to 
tumor promotion, and inhibition of ODC is associated with suppression of tumor 
development in animals (Lan et al, 2000; Love et al, 1993). Overexpression of ODC 
can also induce transformation of cells (Kubota et al, 1997) and ODC-overexpressing 
cells are tumorigenic in mice (Peralta Soler et al, 1998). Even moderate reductions of 
intracellular ODC activity can lead to a resistance in tumor development (Pegg, 2006). 
Overexpression of ODC in hair follicle cells of mice can also lead to hair loss (Soler 
et al, 1996; Wheeler et al, 2003). The effect seems to be attributable to an interference 
of putrescine with hair development (Pietila et al, 1997).  
  Several crystal structures of eukaryotic ODC were reported that include ODC from 
human and Trypanosoma brucei and showed that the active site is composed by both 
subunits of the homodimeric ODC (Almrud et al, 2000; Dufe et al, 2007; Grishin et al, 
1999; Jackson et al, 2004; Jackson et al, 2000; Jackson et al, 2003). Mutations of 
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residues of the dimer interface of ODC significantly decrease the catalytic efficiency 
of ODC (Myers et al, 2001). These ODCs (~ 53 kD) belongs to the alanine racemase?
family (Mehta & Christen, 2000). The crystal structure of human ODC (PDB code: 
1D7K, (Almrud et al, 2000)) has been determined to 2.1 Å resolution with PLP in the 
active site, however it contains no ligands (Fig. 4). The 3D structures of Trypanosoma 
brucei ODC have been solved together with the product putrescine or DFMO (an 
irreversible inhibitor of ODC). In these structures, the ε-amino group of putrescine or 
DFMO is bound between two aspartic acid residues (Asp332 and Asp361) and in 
comparison to the unliganded enzyme the catalytic residue Cys360 is also rotated 
towards the active site (Grishin et al, 1999). The aldehyde group of PLP forms an 
internal Schiff base with Lys69 in hODC or tODC. The pyridine ring of the PLP 
interacts with the side chain of His197 and the N1 of PLP forms a hydrogen bond with 
the side chain oxygens of Glu274. The phosphate group binds into the pocket formed 
by Ala67, Pro275, Gly276, Arg277 and Tyr389 (Red circle, Fig. 4).  
  
 
 
Fig. 4 The crystal structure of the active site of human ornithine decarboxylase 
(PDB code: 1D7K; (Almrud et al, 2000)). PLP is displayed in ball-stick mode and 
residues in stick mode. Red circle, the phosphate binding region; White circle, the 
putative binding region of the ε-amino group of ornithine.  
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1.2.3 Spermine/spermidine N1-acetyltransferase and acetyl polyamine oxidase 
Spermine/spermidine N1-acetyltransferase (SSAT) and acetyl polyamine oxidase 
(APAO) are highly inducible enzymes in polyamine catabolic pathway and are in 
charge of the conversion of the more charged SPM or SPD into the less charged SPD 
or PUT, respectively (Fig. 3, (Casero & Pegg, 1993; Pavlov et al, 2002; Vujcic et al, 
2003)). SSAT catalyzes the formation of N1-acetylspermine or N1-acetylspermidine by 
transfering an acetyl group from acetyl-coenzyme A to the N1 position of either SPM 
or SPD (Casero & Marton, 2007). APAO oxidizes N1-acetylated polyamines and 
produces H2O2, 3-acetoamidopropanal, and either spermidine or putrescine, depending 
on the starting substrate in the presence of molecular oxygen (Fig. 3, (Wang & Casero, 
2006)). Recently, Vujcic et al discovered a novel oxidase, spermine oxidase (SMO), 
which directly oxidizes SPM to SPD, 3-aminopropanl and H2O2, independent of 
SSAT (Vujcic et al, 2003).  
  The 3D structure of SSAT (~ 20 kD), the potential drug target, is already known 
together with its inhibitor N1, N11- di(ethyl)- norspermine (DENspm, Fig. 3; (Bewley 
et al, 2006)) or with N1-spermine-acetyl-coenzyme A, the bisubstrate analog (Hegde 
et al, 2007). The SSAT-catalyzed reaction was confirmed to be the rate-limiting step 
in the two-step catabolic conversion from spermine to spermidine and from 
spermidine to putrescine (Wang & Casero, 2006). The SSAT with a half life of 15 min 
is normally present in very small amounts in the cell and is induced by a number of 
factors including various toxic agents, hormones as well as growth factors, the 
polyamines themselves and polyamine analogs (Casero & Pegg, 1993). Induction of 
SSAT decreases cell growth and increased apoptosis (Babbar et al, 2006). In animal 
studies, this response to polyamine analogs has been demonstrated to be a tumor 
cell–specific response (Gabrielson et al, 2004). Oxidases, APAO and SMO, are 
regarded to be responsible for producing reactive oxygen species that contribute to the 
bioactivity of these polyamine analogs (Casero & Marton, 2007). The H2O2 generated 
in these processes is considered as the main cause for cell death. SMO, like SSAT, is 
significantly induced by polyamine analogs in a dose- and time-dependant manner 
(Devereux et al, 2003). APAO is a generally constitutively expressed, FAD-dependent 
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oxidase. Although APAO activity was not altered significantly under 
pathophysiological conditions, it is also induced by polyamines or polyamine analogs 
in a manner that parallels the induction of SSAT and SMO (Casero & Pegg, 1993; 
Pavlov et al, 2002; Vujcic et al, 2003). This suggests the existence of a common 
regulatory mechanism for all three genes (SSAT, APAO and SMO) (Vujcic et al, 
2003).  
 
1.2.4 Antizyme 
The protein antizyme (AZ) is known to be a regulator of polyamine metabolism that 
inhibits the activity of ODC and polyamine transport, thus restricting cellular 
polyamine levels (Fig. 3, (Coffino, 2001; Pegg, 2006)). The inhibition of ODC by AZ 
functions via the formation of a tight heterodimic complex between AZ and the ODC 
monomer, which prevents enzymic activity and leads to the ubiquitine-independent 
degradation of ODC (Murakami et al, 1992). The half-life of the ODC-AZ complex is 
less than 5 min (Ivanov et al, 2000). The AZ-mediated degradation of ODC has been 
found to be conserved from yeast to human (Palanimurugan et al, 2004). Multiple 
forms of antizyme are expressed in many eukaryotes. AZ-1 (~ 25 kD) and AZ-2 (~ 21 
kD) exist ubiquitously in cells, and AZ-3 (~ 21 kD) only in germ cells of testis 
(Ivanov et al, 2000). The NMR structure of a fragment of the AZ protein (residues 
87–227) has been determined and shows a fold similar to some acetyltransferases 
including SSAT (Hoffman et al, 2005), another regulatory protein of the polyamine 
metabolism. The sequence of AZ-1 contains a group of conserved acidic amino acids 
(Glu161, Glu164, and Glu165) on an external face that may interact with the binding 
element in ODC, which includes an electropositive surface formed by the residues 
117–140 (Coffino, 2001). The production of AZ depends on the polyamine levels 
through an unusual regulatory mechanism, namely a +1 frameshifting, which is 
obligatory for functional AZ production in mammalians (Coffino, 2001). AZ was also 
found to interact with both cyclin D1 and cyclin D1-associated cyclin-dependent 
kinase cdk4. Cyclin D1, like ODC, is degraded by proteasomes in an 
ubiquitin-independent manner (Coffino, 2001; Matsufuji et al, 1995). Overexpression 
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of AZ can also induce apoptosis of cells triggered by mitochondrial membrane 
depolarization and caspases (Liu et al, 2006).  
 
 
1.2.5 Polyamine transporter 
Besides biosynthesis and catabolism, cells are also able to take up polyamines from 
the extracellular environment by an efficient and ATP-dependent polyamine 
transporting system, which is still not well-characterized (Fig. 3, (Igarashi & 
Kashiwagi, 1999; Seiler, 2003)). Moreover, PT can efficiently transport SPD and 
SPM conjugates into cells. Recently, the intracellular concentration of an iron chelator 
conjugate was strongly increased in cells with a factor of 1900 by conjugating with 
spermine. The bioactivity of the conjugate was improved more than 230-fold in 
comparison to the iron chelator alone (Bergeron et al, 2005; Bergeron et al, 2003). 
 
 
1.2.6 Other functions of polyamines 
Recently, polyamines were found to interfere also with different processes or 
molecules in cells, such as inflammation, acetylation and membrane receptors. 
Spermine was identified to have anti-inflammatory properties, and depletion of 
polyamines by DFMO could abolish neurodegeneration and increase the survival rate 
of mice, which were exposed to severe innate immune reactions in the CNS (Soulet & 
Rivest, 2003; Zhang et al, 2000). Endogenous polyamines can regulate the expression 
of nitric oxide synthase (Baydoun & Morgan, 1998) which is an inducible enzyme 
involved in the early phase response to inflammatory insults and produces high-output 
of NO (Satriano, 2004).  
   Intracellular polyamines can also alter the expression and activity of both histone 
acetyltransferases (HAT) and histone deacetylases (HDAC). These two enzymes 
determine steady-state levels of histone acetylation (Hobbs & Gilmour, 2000) in 
proliferating cells (Wei et al, 2007). HDAC is an emerging anti-cancer target and the 
inhibition of HDAC can lead to a cell-cycle arrest, apoptosis and, in some cases, 
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differentiation (Carey & La Thangue, 2006; McLaughlin & La Thangue, 2004). Many 
pharmaceutical companies are developing HDAC inhibitors and several have passed 
the earlier clinical trials and exhibited generally a favourable toxicity profile (Carey & 
La Thangue, 2006; Inche & La Thangue, 2006). The intracellular ODC activity was 
also reported to closely correlate with the sensitivity of cells to HDAC 
inhibitor–induced apoptosis (Saunders & Verdin, 2006). Polyamines are also known 
to bind membrane or intracellular receptors. Polyamines have been suggested to 
interact with several ion channels and receptors involved in the regulation of calcium, 
sodium, and potassium homeostasis (Li et al, 2007). Spermine was also found to 
facilitate binding of the estrogen-ERα complex to estrogen-responsive elements (ERE) 
(Thomas et al, 1999) and polyamine analogs were also reported to down-regulate ERα 
expression in human breast cancer cells (Huang et al, 2006). 
 
 
1.3 Inhibitors of polyamine metabolism 
 
1.3.1 DFMO, an irreversible inhibitor of ODC 
Numerous inhibitors of hODC are known and some of them are in clinical studies as 
anti-cancer agents. The best-known is DFMO, an irreversible inhibitor of hODC. 
DFMO (Fig. 2) is a suicide inhibitor of ODC and binds irreversibly to Cys360 of the 
holo enzyme after being activated by ODC. It was initially developed as an 
anti-cancer agent in the eighties with the aim of targeting human ODC. Later on, it 
turned out to be a potent therapeutic agent against sleeping sickness as it targets ODC 
of Trypanosoma brucei even better. Nowadays, DFMO is still used as a first-line drug 
to cure sleeping sickness (Heby et al, 2007) and as a remedy against facial hair 
growth in women (Shapiro & Lui, 2005).  
  Clinical studies proved that DFMO is a well-tolerated agent but not as efficient, as 
initially thought, to treat cancers. This seems to be due to its low affinity (Ki ~ 40 
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µM), fast clearance, inefficient uptake into cells, and development of cell resistance 
that is due to up-regulation of ODC expression and polyamine transport (Casero et al, 
2005; Marton & Pegg, 1995; Seiler, 2003). Never the less, some positive results with 
DFMO have been achieved in the treatment of recurrent anaplastic gliomas (Wallace 
& Fraser, 2004). Clinical phase II and III studies of DFMO as an anti-cancer or 
chemopreventive agent are still on going be it as a single agent or in combination with 
other drugs (Messing et al, 2006; Raul et al, 2007; Vlastos et al, 2005).  
  A lot of attempts have been made to modify the ornithine skeleton of DFMO to 
improve the efficiency of DFMO (Seiler, 2003). Although the modified compounds 
had improved binding affinity for ODC in vitro, they were not more effective 
inhibiting cell proliferation in vitro and in vivo (Seiler, 2003). Thus, inhibitors of 
hODC with better efficiency in suppressing the proliferation of tumor cells are in high 
demand. 
 
 
1.3.2 Polyamine analogs or mimics 
Polyamine analogs are derivatives of natural polyamines and sufficiently similar in 
structure to the parent compound to allow their recognition and subsequent uptake by 
the polyamine transporter. However, they cannot be converted further in cells by 
polyamine catabolic enzymes due to missing free amino groups (Wallace et al, 2003). 
These analogs cause a multi-target inhibitory effect. They not only compete with the 
natural polyamines for uptake by the polyamine transporter but also induce the 
activities of AZ, SSAT and PAO and decrease ODC activity. The development of 
polyamine analogs or mimics has been started more than 20 years ago (Seiler, 2005). 
The original idea was to develop mimics of natural polyamines to modulate directly 
polyamines biosynthesis (Berger & Porter, 1986). Further studies revealed that one 
class, the bis(ethyl)polyamine analogs, drastically induce the SSAT activity more than 
1700-fold (Casero et al, 1989), and inhibit cell proliferation significantly. This finding 
prompted the cloning of SSAT (Casero & Marton, 2007). DENspm is one of the most 
effective inducers (Fig. 5) and also known as BENspm or BE333. Now, it is in clinical 
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studies, but showed some unacceptable toxicity similar to that of the polyamine SPM 
in the high-dose range (Casero & Marton, 2007; Seiler, 2003). 
 
N
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Fig. 5 The chemical structure of DENspm.  
 
 
1.4 Human histidine decarboxylase 
 
L-Histidine decarboxylase (HDC), a dimeric PLP-dependent enzyme, is the 
rate-limiting enzyme for histamine synthesis in mammals (Medina et al, 2003). The 
biogenic amine histamine plays physiologically and pathologically important roles in 
inflammation, gastric acid secretion, neurotransmission, and immune modulation, 
particularly in allergic reactions by acting on its specific membrane receptors, H1, H2, 
H3, and H4 (Furuta et al, 2007). The formation and release of histamine have been 
implicated in gastric mucosal damage caused by drugs like aspirin (Parmar et al, 
1984). Therefore, HDC can be regarded as a potential target to attenuate histamine 
production in certain pathological states (Medina et al, 2003; Moya-Garcia et al, 
2005).  
   A 3D model has been constructed using the crystal structure of pig dopa 
decarboxylase as the template (Fig. 6A), as described in more details in 4.2. Different 
types of inhibitors of histidine decarboxylase have been discovered already 20 years 
ago, i.e. histidine methyl ester, α-fluoromethylhistidine and His-Phe or more recently, 
i.e. epigallocatechin gallate (EGCG) (Fig. 6B).  
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Fig. 6 Structures of rat histidine decarboxylase and inhibitors. A) Stereo view of 
the predicted active site of rat HDC with the cofactor PLP (pink) (Fleming et al, 
2004). B) Known inhibitors of mammalian HDC. 
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1.5 Inhibitor design 
 
1.5.1 Transition state-based ligand design 
Transition-state-based inhibitors bind with high affinity to their target enzyme. 
Designing of transition-state inhibitors is used frequently in drug discovery 
(Robertson, 2005). Recently, a class of transition state-based inhibitor (intermediate 
mimics) of purine nucleoside phosphorylase showed excellent binding affinity (Taylor 
Ringia & Schramm, 2005). The designed immucillinH, an inhibitor of human purine 
nucleoside phosphorylase, with a Kd of 56 pM, is in clinical phase IIa to treat T cell 
leukemia (www.biocryst.com) (Basu et al, 2007; Singh et al, 2005). 
   Designing inhibitors by mimicking well-defined reaction intermediates is a 
powerful strategy in developing potent and specific inhibitors for PLP-dependent 
enzymes. In all PLP-dependent enzymes, the external aldimine, a Schiff base of PLP 
with the α-amino group of the amino acid substrate, is a common intermediate. 
Reduction of the Schiff base produces phosphopyridoxyl-amino acid conjugates, 
analogs of the covalent intermediates (Fig. 1 and 7). These compounds are a kind of 
transition state analogs that bind to the apoprotein with high affinity (Heller JS, 1975; 
Khomutov et al, 1971; Raso & Stollar, 1975). They cannot be transformed by the 
enzymes and thus inhibit them very potently. A future advantage of these analogs is 
that they bind with high specificity to the respective apoenzymes. Binding studies 
with phosphopyridoxyl-amino acids showed that phosphopyridoxyl-L-aspartate and 
phosphopyridoxyl-L-glutamate, in contrast to phosphopyridoxyl-L-tyrosine and 
phosphopyridoxyl-L-alanine, bind so tightly to aspartate aminotransferase that they 
could not be competed away by PLP, which has a high affinity for this enzyme. 
Phosphopyridoxyl-ornithine was found to be an inhibitor of ornithine decarboxylase 
(ODC) but did not affect S-adenosylmethionine decarboxylase (Heller JS, 1975). The 
drawback of these compounds in their in vivo application is the impermeability to the 
cell membranes for these substances due to their negative charges. On incubation of 
fibroblasts with phosphopyridoxyl-L-aspartate or L-glutamate, neither uptake nor any 
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effect on the cells could be demonstrated (H. Gehring personal communication) which 
is in agreement with results reported for phosphopyridoxyl-L-ornithine (Coward & 
Pegg, 1987). Thus, if one succeeds to expose newly synthesized cellular ODC to 
phosphopyridoxyl-ornithine, ODC activity can be expected to be completely and 
specifically inhibited (no mammalian α-transaminase for ornithine is known) and 
consequently stop the cell proliferation. Human ODC, the potential anti-cancer target, 
decarboxylates the substrate through a well defined process (Jackson et al, 2000). CO2 
release, accompanied by formation of the quinonoid intermediate, is an irreversible 
step and has been identified as the likely rate-determining step in the enzymic reaction 
(Fig. 7). Therefore, designing cell-permeable analogs that mimicking the external 
aldimine intermediate could be a strategy to develop novel inhibitors for hODC.  
 
 
Fig. 7 Reaction mechanism for ODC. Obtained from K. Laurie (Jackson et al, 
2000). 
 
 
1.5.2 Structure-based ligand design 
Structure-based drug design becomes more and more important in developing 
inhibitors due to the increased numbers of 3D structures of proteins, the high 
computational efficiency in molecular modeling and calculation and the accessibility 
of user-friendly software. Up to now, there are several drugs on the market that 
originated from structure-based approaches (Singh et al, 2006). Agenerase and 
Viracept, e.g., were developed using the crystal structure of HIV protease (Lapatto et 
Quinonoid 
General introduction                                                   24                
 
al, 1989) and the flu drug Relenza was also designed based on the crystal structure of 
neuraminidase (Wade, 1997). Dozens of compounds (>40) have been discovered with 
the aid of structure-guided methods and have entered clinical trials. Identifying novel 
hydrophobic sites in the active site of enzymes and designing additional molecular 
fragments that will occupy them can improve the binding affinity and is a common 
strategy to develop improved inhibitors based on the structure of known inhibitors 
(Knight et al, 2006; Singh et al, 2005). PIK-294, a newly reported inhibitor of 
phosphoinositide 3-kinases (PIK3), which has an additional m-phenol group 
compared to the parent compound PIK-293 projects into a deeper binding pocket that 
is not accessed by the co-substrate ATP and by PIK-293. It potency was increased 
10-60 folds towards the different isoforms of phosphoinositide 3-kinases (Knight et al, 
2006). 
  Structure-based drug design can be classified into two applicable strategies, namely 
high-throughput database screening and fragment-based ligand de novo design. High- 
throughput database screening requires high computational efficiency, as usually a 
known chemical database containing hundreds of thousands of compounds have to be 
screened against the whole binding site of targeted proteins. Fragment-based de novo 
drug design usually identifies fragments of a few atoms to fit in specific pockets of 
the binding site. Fragment-based de novo drug design can also generate new chemical 
entities with desired properties in a cost- and time-efficient manner (Singh et al, 2006). 
LUDI, a structure-based de novo drug design software, was developed in the early 
nineties, based on an empirical scoring function (Bohm, 1994). It can efficiently 
identify small molecular fragments (5-30 atoms) from a fragment library (~1000) to 
fit into the binding pocket of proteins de novo and/or append new substitutions to an 
already existing anchor ligands under consideration of steric constraints (Bohm, 1992). 
Successful applications of LUDI have been reported in many cases, such as the design 
of improved inhibitors for HIV protease and dihydrofolate reductase. Using LUDI to 
place fragments in the binding pocket also helps mapping binding constraints in the 
binding sites (Singh et al, 2006).  
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1.5.3 Design of improved and cell-permeable ligands for hODC and hHDC 
Studying the interaction between analogs of reaction intermediates as discussed above 
and the active site of enzymes and exploring the 3D geometry of the binding site by 
using structurally diverse mimics is a reasonable strategy for discovering improved 
inhibitors.  
To find more potent cell-permeable inhibitors for intracellular hODC or hHDC, 
different molecular mimics of reaction intermediates were designed and synthesized 
by conjugating pyridoxal or pyridoxal 5’-phosphate with substrate derivatives. These 
conjugates with a methyl ester-protected carboxylate group may be expected to be 
cell-permeable precursors of potentially intracellular active inhibitors because they 
have no negative net charge and very likely cross the cell membrane as it was reported 
for several pyridoxyl-amines (Zhang & McCormick, 1992; Zhang & McCormick, 
1991) and a pyridoxyl-methionine analog (Ogier et al, 1993). Intracellular pyridoxal 
kinase, an enzyme that seems to tolerate considerable variation in C4’ position of the 
pyridoxyl moiety (Tang et al, 2005; Zhang & McCormick, 1991), is expected to 
phosphorylate these compounds (Zhang et al, 1993) after they have been taken up by 
the cells; whereas the carboxymethyl ester will be hydrolyzed intracellularly (Kelley 
et al, 1977). The active form of the conjugates formed in the cells will bind with very 
high affinity to the newly synthesized apoenzymes, thus affecting only proliferating 
cells, in which hODC or hHDC is obligatorily induced.  
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1.6 Aims of the thesis 
 
PLP-dependent enzymes catalyze manifold transformations of amino acids such as 
transamination, α-decarboxylation, and racemization, as well as β- or γ-elimination 
and replacement reactions. As vitamin B6-dependent enzymes play a central role in 
amine and amino acid metabolism, they are interesting targets for drugs to intervene 
in specific processes that lead to pathological states. Human ornithine decarboxylase 
(ODC) and histidine decarboxylase (HDC) are pyridoxal 5’-phosphate 
(PLP)-dependent enzymes. They are responsible for synthesis of biogenic polyamine 
or histamine in cells and regarded as anti-cancer or anti-histamine targets, respectively. 
Cell-permeable inhibitors of these enzymes are in demand as (see 1.3.1 and 1.5.1) to 
antagonize the production of polyamines and histamines in certain pathologic 
conditions. Phosphopyridoxyl-amino acid adducts, a kind of transition state analogs of 
vitamin B6-dependent enzymes, bind with very high affinity and specificity to their 
respective enzymes. The drawback of these compounds in their in vivo application is, 
however, the impermeability of the cell membranes due to their negative charges. 
Thus, derivatives of phosphopyridoxyl-amino acid adducts that are expected to be 
taken up by cells should be developed and tested for their inhibitory capability for a 
particularly intracellular vitamin B6-dependent enzyme and/or for cell proliferation in 
the case of ODC. From this investigations, information on the structural features of 
covalent pyridoxyl-amino acid derivates that facilitate their uptake by cells were 
expected as well as whether such compounds could be potentially useful 
anti-neoplastic drugs.  
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2.1 Abstract 
 
Pyridoxal 5’-phosphate (PLP)-dependent ornithine decarboxylase (ODC) is the key 
enzyme in polyamine synthesis. ODC is overexpressed in many tumor cells and thus a 
potential drug target. Here we show the design and synthesis of a coenzyme-substrate 
analog as a novel precursor inhibitor of ODC. Structural analysis of the crystal 
structure of hODC disclosed an additional hydrophobic pocket surrounding the 
ε-amino group of its substrate ornithine. Molecular modeling methods showed 
favorable interactions of the BOC-protected pyridoxyl-ornithine conjugate, termed 
POB, in the active site of hODC. The synthesized and purified POB completely 
inhibited the activity of newly induced ODC activity at 100 µM in glioma LN229 and 
COS7 cells. In correlation with the inhibition of ODC activity, a time dependent 
inhibition of cell growth was observed in myeloma, glioma LN18 and LN229, Jurkat, 
COS7 and SW2 small-cell lung cancer cells if DNA synthesis and cell number were 
measured, but not in the non-tumorigenic human aortic smooth muscle cells. POB not 
only strongly inhibited cell proliferation of low grade glioma LN229 cells in a dose 
dependent manner (IC50 ~ 50 µM) but also high grade glioblastoma multiforme cells. 
POB is much more efficient in inhibiting proliferation of several types of tumor cells 
than α-DL-difluoromethylornithine (DFMO), the best known irreversible inhibitor of 
ODC.  
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2.2 Introduction  
 
Polyamines, such as putrescine (PUT), spermidine (SPD) and spermine (SPM) are 
multi-charged aliphatic cations and exist in all organisms (1). Ornithine decarboxylase 
(ODC), a pyridoxal 5’-phosphate-dependent enzyme, catalyzes the conversion of 
ornithine to putrescine, the first and rate–limiting step in polyamine synthesis (Fig. 1A) 
(2). ODC expression is rapidly induced after exposing cells with cell 
proliferation-stimulating agents (2-4). High levels of ODC observed in cancer cells 
are closely related to tumor promotion (1, 5). Overexpression of ODC induces 
transformation of cells (6) and inhibition of ODC abolishes transformation and is 
associated with tumor suppression (2, 7). Even modest reductions in ODC activity can 
lead to a marked resistance in tumor development (2, 7). ODC-overexpressing cells 
are tumorigenic and expression of ODC in hair follicle cells is linked to growth and 
maintenance of hair follicles (8). Thus, ODC is an interesting target for anti-cancer or 
chemopreventive drugs (2, 5).  
  Several inhibitors of ODC are known and the most widely used compound is 
α-DL-difluoromethylornithine (DFMO), an enzyme-activated irreversible inhibitor, 
which was introduced more than 20 years ago. DFMO irreversibly binds into the 
active site of ODC by covalently attaching to Cys360 after it is activated by ODC 
itself (5). Although DFMO has been shown to be effective in some experimental 
models and therapeutical approaches, it seems not to be as effective in vivo against 
tumor cells (9). One explanation of why DFMO is not sufficiently blocking ODC 
activity in vivo might be that DFMO is displaced, due to its relatively low affinity (Ki 
~ 40 µM), by endogenous ornithine (Km ~ 90 µM), the substrate of ODC (5). The 
concentration of ornithine in human plasma seems to be in the range of this Km value. 
Fast clearance, inefficient uptake into cells and development of resistance, such as 
up-regulation of ODC expression and polyamine transporter, are further drawbacks of 
DFMO (5, 10, 11). Thus, other ODC inhibitors which have higher potency, better 
pharmacokinetics and the ability to overcome the cell resistance are demanded (5, 10). 
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A lot of attempts have been made by modifying the ornithine skeleton structure of 
DFMO to improve the efficiency (5). Although the modified compounds got 
improved binding affinity for ODC in vitro, they had no favorable effect in inhibiting 
cell proliferation in vitro and in vivo (5). 
  Pyridoxal 5’-phosphate (PLP) is the functional cofactor of PLP-dependent enzymes 
which catalyze a wide variety of amino acid transformations (12, 13). An obligatory 
step in all these reactions is the intermediary formation of an aldimine, i.e. a Schiff 
base of PLP with the amino group of the amino acid substrate (Fig. 1A) (12, 13). 
Reduction of the Schiff base produces phosphopyridoxyl-amino acids, which are 
analogs of the covalent coenzyme-substrate adducts. These compounds are a kind of 
transition state analogs that bind to the apoprotein with high affinity (14-16). They 
cannot be transformed by the enzymes and thus inhibit them very potently. A further 
advantage of these analogs of coenzyme-substrate adducts is the high degree of 
specificity. Phosphopyridoxyl-ornithine was found to be a very potent inhibitor of 
ornithine decarboxylase without affecting S-adenosylemethionine decarboxylase (15). 
  Successful exposure of newly synthesized cellular ODC to 
phosphopyridoxyl-ornithine would inhibit ODC activity completely and specifically 
(no mammalian α-transaminase for ornithine is known), and thus induce the inhibition 
of cell proliferation. However, the drawback of these compounds in their in vivo 
application is the impermeability of the cell membrane for these substances due to 
their negative charges.  
  Here we report the design and synthesis of a phosphopyridoxyl-ornithine based 
precursor inhibitor for human ornithine decarboxylase which can be taken up by cells. 
POB (Fig 1B) inhibited ODC activity in cells and inhibited proliferation of many 
types of tumor or transformed cells much more effectively than DFMO. 
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2.3 Materials and Methods 
 
Chemicals and Cell lines 
Pyridoxal•HCl was purchased from Merck. H-Orn(BOC)-OMe•HCl and DFMO 
were from Bachem. L-[1-14C]ornithine and [3H]thymidine were from American 
Radiolabeled Chemicals Inc. 
  NIH3T3 cells were purchased from American Type Culture Collection. Glioma cell 
line LN18, LN229 (both from brain), primary tumor cells from lung cancer metastasis 
in brain (LCMB) and from glioblastoma multiforme (GBM) were generous gifts from 
Dr. K. Frei (Department of Neurosurgery, University Hospital Zurich). COS7 cells 
(monkey kidney, SV40 T antigen transformed) and a murine myeloma cell line were 
generous gifts from Prof. P. Sonderegger (Department of Biochemistry, University 
Zürich). Jurkat cells (a tumor T lymphoma cell line) and a human small-cell lung 
cancer cell line (SW2) were kindly provided by Dr. J. Kemler-Carraneo (Abteilung 
Klinische Immunologie, University Hospital Zurich). Human aortic smooth muscle 
cells were gifts from Dr. C. Dumrese (Anatomische Institut, Universität Zürich).  
 
  Synthesis of POB 
N-(4’-pyridoxyl)- ornithine(BOC)-OMe•HCl (POB, Fig. 1B) was synthesized as 
described for the synthesis of phosphopyridoxyl-ornithine or pyridoxyl-ornithine (15). 
Briefly, pyridoxal (1mmol) and KOH (2 mmol) were dissolved in 5 ml methanol as 
was H-Orn(BOC)-OMe•HCl (1 mmol) and KOH (1 mmol) in 8 ml MeOH. Both 
solutions were mixed at 0 ºC and stirred at room-temperature for 20 min. Then, 125 
mg of NaBH4 was added in small portions and the solution was put on ice for further 
30 min. Acetic acid (100%) was added until pH 5 was reached to stop the reaction. 
The solvents were removed with a vacuum dryer and the residue was dissolved in 
water and subjected to HPLC for purification and analysis. 
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HPLC analysis and purification of POB 
The compound was analyzed and purified with a Jasco HPLC equipped with a 
Nova Pack C18 column (3.9×150 mm, 5 µm from Millipore) and a multiwavelengh 
detector. The sample was loaded and separated with a flow rate of 0.5 ml/min using 
the following gradient: 0-12 min, 100% solvent A (3% ACN/0.1% TFA) and 0% 
solvent B (80% ACN/0.1% TFA); 12-22 min, 0-80% B; 22-92 min, 80-100% B, 
followed by 100% B. The detection was carried out at 290 and 215 nm. Under these 
conditions the synthetic compounds eluted at the retention time of 21.4 min and the 
MS peak of this purified compound is 398.22 Dalton (purity >95%, Supplementary Fig. 
S1). 
  The extinction coefficient used for this compound was 8400 M-1cm-1 at 296 nm 
under acidic conditions (17). A semi-prep column (aquapore octyl, 10×250 mm, 20 
µm) was used under similar conditions to prepare larger amounts of POB. The 
purified POB was vacuum-dried several times after adding water and stored at a 
concentration of about 10 mM (water stock solution) in –20 °C. 
 
  Cell culture 
  LN18, LN229, LCMB and GBM were maintained in DMEM supplemented with 
1 g/L glucose, 10% FBS (Life Technologies), 20 µg/ml gentamycine (Fluka) in a 
humidified 5% CO2 atmosphere at 37 °C. Jurkat cells were grown in RPMI 1640 
medium (Sigma) supplemented with 10% NBCS (Life Technologies), 15 mM Hepes 
(Life Technologies), 2 mM L-glutamine, 50 µM β-mercaptoethanol, and 1% (w/v) 
penicillin and streptomycin (Life Technologies) in a humidified 5% CO2 atmosphere 
at 37 °C. SW2 cells were grown in RPMI 1640 supplemented with 10% FBS. 
NIH3T3 and myeloma cells were maintained in DMEM medium with 10% NBCS or 
FBS. The human aortic smooth muscle cells were cultured in DMEM containing 10% 
FBS, 20 mM HEPES buffer solution in a humidified atmosphere (5% CO2). 
  For measuring cell growth, cells (2.5 - 5 x 104 cells per well) were seeded and 
incubated in 0.5 ml medium containing 5% FBS or NBCS and 1% 
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penicillin/streptomycin in 24-well plate. After one day, cells were incubated in the 
absence or presence of the indicated concentrations of POB or DFMO for the 
indicated times. Cells were counted with a Coulter counter (ZM Coulter Electronics) 
as described (18). Data in the figures represent a typical experiment out of at least two 
independent experiments. 
 
[3H]thymidine incorporation 
  Cells were seeded and pretreated as described above. Then, [3H]thymidine (0.25 
µCi) was added into each well and incubated together with cells for the indicated 
times. Radioactivity of incorporated [3H]thymidine was measured in a Wallac 1450 
MicroBeta liquid scintillation counter according to the procedure described by Koga 
et al. (19). The numbers in the figures are the mean of at least three wells. 
  ODC activity 
ODC activity was measured by the released 14CO2 from labeled ornithine as 
described (20). For measuring the serum-induced ornithine decarboxylase activity, 
cells were cultured in 6-well plate at a density of ~1.6 x 105 per well with 5% FBS or 
NBCS for one day and then treated in the absence or in the presence of POB for the 
indicated times. The cells were then induced by fresh medium containing 10% FBS 
for 6 h, collected after trypsine/EDTA treatment and washed twice with ice-cold 
phosphate-buffered saline, pH 7.4 (PBS). The collected cells were lysed two times by 
freezing (liquid nitrogen) and thawing (37 °C, 2 min) in 320 µL lysis buffer (1 mM 
EDTA, 100 µM pyridoxal phosphate, 2.5 mM DTT and protease inhibitor cocktail 
(Roche) in 50 mM PBS, pH 7.4). The reaction was started by adding 30 µl L-[1-14C] 
ornithine (100 µM, 0.09 µCi) to 270 µl supernatant of lysed cells. After 75 min 
incubation, the reaction was stopped by injecting 200 µL 4 N H2SO4 and kept for one 
hour at room temperature in order to ensure complete absorption of released CO2 in 
the capture reagent (tissue solubilizer NCSII, Amersham). The captured 14CO2 was 
measured by scintillation counting using a Wallac 1450 MicroBeta liquid scintillation 
counter. The protein concentration in the lysed supernatant was determined by the 
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BioRad protein assay kit. The numbers in the figures are the mean of at least two 
wells. 
 
Western blotting  
LN229 Cells were seeded in 25-cm2 flasks (~4 x 105 cells) and treated in the 
absence or presence of POB for three days and lysed as described above. Cell lysates 
were fractionated on 10% SDS-PAGE and subjected to immunoblotting analysis as 
described (21).  
 
Polyamine analysis 
  LN229 cells were seeded in 6-well plate at a density of ~1.6 x 105 per well with 5% 
FBS for one day and then treated in the absence or presence of POB (100 µM) for the 
indicated times. Cells were collected, counted and lysed. Polyamines were extracted 
with 0.2 M perchloric acid and measured by Dr. L. Persson and coworkers 
(Department of Experimental Medical Research, Lund University) as described (22). 
The numbers in the figures are the mean of triplicates. 
 
  Polyamine oxidase  
  Polyamine oxidase activity was determined as described (23). LN229 cells were 
seeded in 6-well plate at a density of ~1.6 x 105 per well with 5% FBS for one day 
and treated in the absence or presence of POB (200 µM) or DFMO (500 µM) for the 2 
days. Then, cells were lysed and polyamine oxidase activities measured. The numbers 
in the figures are the mean of triplicates. 
  
  Molecular modeling 
The model containing human ODC, PLP and putrescine was generated by 
superposition of the crystal structure of the human ODC (PDB code: 1D7K, Fig 2A 
(24)) with the crystal structure of Trypanosoma Brucei ODC (PDB code: 1F3T, (25)) 
containing PLP and putrescine as ligands. In order to optimize the structure of the 
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complex formed with PLP, putrescine and human ODC protein, energy minimization 
was performed by using InsightII software (version 2000, Accelrys Corporate) under 
amber force field. The putative binding sites of hODC in this model were analyzed 
with InsightII binding site module and prepared for further docking analysis by using 
DOCK4 (USCF) without considering the solvent effect. DOCK4 was employed for 
predicting the geometry of the ligands bound to the protein (26). Electrostatic and van 
der Waals energies were evaluated on a grid with a 0.3 Å spacing in the region 
spanning all residues within 6 Å of phosphopyridoxyl-putrescine adduct (see Fig. 1A 
and 2B). The structures of phosphopyridoxyl-ornithine (Schiff base analog, Fig. 1) 
and the putative active form of POB (Fig. 2C) were drawn based on the known 3D 
coordinates of the phosphopyridoxyl-putrescine conjugate followed by energy 
minimization. The optimized structures were rigidly docked into the modeled active 
site of ODC using the program DOCK4 and the complexes of ODC and analogs were 
further optimized by energy minimization (InsightII) (Fig. 2C). The de novo design 
program LUDI (27) of InsightII was used to retrieve putative fragments which can fit 
into the binding pocket (Fig. 2B). The standard default parameter and a fragment 
library supplied with the program were used for the LUDI search. 
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2.4 Results 
 
Design and modeling of an inhibitor for human ornithine decarboxylase 
The phosphopyridoxyl-ornithine precursor which we designed, synthesized, purified 
(see Materials and Methods) and expected to be able to pass the cell membrane, is 
shown in Fig. 1B. In this pyridoxyl-ornithine derivative, the 5’-phosphate group is 
eliminated and the carboxyl group is esterified with methanol.   The crystal structure 
of human ODC (PDB code: 1D7K) contains the cofactor pyridoxal 5'-phosphate (PLP) 
but no substrate or product (24). In order to study the potential interaction between 
inhibitors and hODC, we built a model composed of the reaction intermediate 
phosphopyridoxyl-putrescine adduct and the active site of hODC (Fig. 1A and 2B) 
(see Materials and Methods). Based on this model and by using the binding site 
analysis module of InsightII, we found a hydrophobic pocket, where the ε-amino 
group of ornithine was situated, that is formed by the aromatic residues TyrA389, 
TyrA331, PheB397 and TyrB323 between the two ODC subunits (Fig. 2B and 2C). 
Only the dimer of ODC is catalytically active, as the active sites are constructed of 
residues from subunit A and B. Applying the structure-based drug design software 
LUDI (InsightII) indicated that fragments such as 1-methylaminoethanol, 
2-aminopyrrole, triethylamine and trimethylamine would fit into this additional 
pocket. Indeed, when the hydrophobic BOC group was added to the ε-amino group of 
ornithine (Fig. 1B), the interaction was more favorable if analyzed by the software 
DOCK or InsightII.  
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Figure 1.  A, Reaction mechanism of ODC with L-ornithine. E-PLP, ODC-pyridoxal 
5’-phosphate (internal aldimine); ES-PLP, enzyme-coenzyme-substrate intermediate 
(external aldimine) B, POB, the precursor analogue of phosphopyridoxyl-ornithine 
(see ES-PLP). 
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Figure 2.  Modeling the phosphopyridoxyl-ornithine analogs in the active site of human ODC. A, 
Stereo view of the dimeric human ODC. The two subunits are colored in green (subunit A) and blue 
(subunit B) and the cofactor PLP in the active site of hODC is shown in CPK mode in yellow. B, The 
Connolly surface of part of the active site is displayed as grey solid surface (generated by residues 
TyrA331, TyrA389, AlaA393, TyrB323, and PheB397) together with the reaction intermediate 
phosphopyridoxyl-putrescine adduct (see Fig. 1A) in yellow (phosphopyridoxyl moiety) and green 
(putrescine moiety). The additional pocket is indicated by a black circle. C, Stereoview of the putative 
binding mode of the active form of POB in the active site of hODC. The Connolly surface of whole 
active site is displayed by dots. Blue, indicates positive charged surface; red, negative and white, 
neutral. The phosphopyridoxyl-ornithine-BOC conjugate is displayed in yellow (phosphopyridoxyl 
moiety) and green (ornithine-BOC moiety). 
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Inhibition of cellular ODC activity 
To prove whether POB (synthesis and purification see Materials and Methods) could 
enter cells and is there converted to an active inhibitor of newly expressed ODC 
activity, COS7 and glioma LN229 cells were subjected to POB. In COS7 cells nearly 
complete inhibition of the activity of ODC was measured after two days of POB 
treatment at a concentration of 100 µM (Fig. 3A). A strong inhibition was also 
observed after 3 days of treatment of LN229 cells with POB at 100 µM, comparable 
with the inhibition of DFMO at a concentration of 500 µM (Fig. 3B). To demonstrate 
whether the diminished ODC activity was indeed due to the inhibition of enzymic 
activity and not to a decreased expression of ODC, Western blot was performed to 
estimate the amount of ODC in LN229 and COS7 cells after treating them with POB 
for 3 or 2 days, respectively (Fig. 3C, for COS7 see Supplementary Fig.S2). The result 
showed that the amount of ODC (53 KD) was similar in POB-treated and control cells. 
Although ODC activity was almost completely inhibited by POB, the amount of ODC 
seemed not to be affected by the inhibition. Thus, POB was taken up by cells and 
acted as proposed as an efficient inhibitor of ODC in cells.  
 
 
Figure 3.  Inhibition of ODC activity in cells by POB. A, COS7 cells were treated with POB (100 
µM) for 2 days. Cells were collected, lysed and ODC activity measured immediately by the release of 
labeled CO2 from ornithine (see Materials and Methods). B, LN229 cells were treated with POB (100 
µM) or with DFMO (500 µM) for the indicated times. Cells were collected, lysed and ODC activity of 
untreated cells (gray columns) or treated cells (black columns) was measured immediately. C, Western 
blot of ODC after treatment of LN229 cells with POB (100 µM) for 3 days. Cells were collected, lysed 
and twofold Laemmli buffer was added to aliquots of the supernatant. The same amount of total 
proteins (47µg) was subjected to SDS-PAGE followed by immunoblotting and Ponceau S staining (see 
Materials and Methods). The main band of 53 KD represents ODC (Control 100%, Treated 106%). 
Error bars represent the standard deviation. 
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Effect of POB on cellular DNA synthesis  
As POB was found effective in inhibiting activity of ODC, and ODC is associated 
with cell proliferation and tumor growth (see Introduction), the effect of POB on 
cancer cell proliferation was investigated with cell lines such as myleoma, human 
small-cell lung cancer cells (SW2), glioma LN229 cells and recently isolated primary 
tumor cells derived from lung cancer metastasis in brain (LCMB) as well as 
glioblastoma multiforme primary tumor cells (GBM) (see Materials and Methods). 
The result showed that in these cells, the DNA synthesis was strongly inhibited upon 
POB treatment (Fig. 4). Myeloma cells were highly sensitive to POB (Fig. 4A). Even 
after adding 50 µM POB only for one day, DNA synthesis measured after a 13-h pulse 
with [3H]dThd was less than 20% of untreated cells. In SW2 cells, the DNA synthesis 
of cells treated with 200 µM POB was reduced to about 15%, whereas the incubation 
with DFMO at the same concentration had no influence. DNA synthesis of LN229 
was decreased to about 25% of the control when exposing them to 100 µM POB for 
one day (Fig. 4C), and that of LCMB and GBM cells to about 33% and 60% of the 
control, respectively after four days treatment (Fig. 4D). 
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Figure 4.  Inhibition of cell DNA synthesis by POB. A, Myeloma cells were pretreated with POB at 
the indicated concentrations for one day, then [3H]dThd was added, incubated for 13 hours and the 
incorporated [3H]dThd was measured (see Materials and Methods). B, SW2 cells were pretreated with 
POB or DFMO for half a day and then incubated with [3H]dThd for 25 hours. C, LN229 cells were 
pretreated with 100 µM POB for one day, and [3H]dThd was added and incubated for the indicated 
times. D, Lung cancer metastasizing cells in brain (LCMB) or glioblastoma multiforme cells (GBM) 
were pretreated with 100 µM POB for four days, and [3H]dThd was added and incubated for the 
indicated times. Gray columns, without treatment; black columns, with POB treatment. Error bars 
represent the standard deviation. 
 
Inhibiting tumor cell growth 
Cell growth of several different types of cell lines in culture was investigated by 
counting the cell number. After treating them with POB or DFMO for the indicated 
time and concentration (Fig. 5A-C), POB at 100 µM was a stronger inhibitor of cell 
growth than DFMO even at 5 or 10-fold higher concentrations in LN229 and COS7 
cells, respectively. Whereas in myeloma cells, POB acted at the indicated 
New transition state-based inhibitor for human ornithine decarboxylase inhibits growth of tumor cells        49 
 
concentration without a delay, in other cells, growth decreased drastically after a delay 
of one or two days. POB also inhibited other cells from different tissues, for instance, 
Jurkat (T cell line), LN18 (brain), and NIH3T3 (fibroblast) cells, whereas 
non-tumorigenic human aortic smooth muscle cells were resistance to inhibition with 
POB (Fig. 5D, the cell number of human aortic smooth muscle cells increased 
2.5-fold during the indicated times). The dose and time dependence of inhibition of 
cell growth by POB varied and was dependent on the cells used and the treatment 
period. For LN229 cells, the IC50 value is around 50 µM when estimated by [3H]dThd 
incorporation or by cell counting after 5 or 6 days of POB exposure (Fig. 6, data of 6 
days treatment not shown). The cell inhibition with DFMO was less effective than 
that with POB at the indicated concentrations (Fig. 6). 
 
 
 
Figure 5.  Cell growth inhibition of POB and DFMO. Myeloma cells A, Glioma LN229 cells (B) 
and COS7 cells (C) were treated without (●) or either with POB (■, 100 µM) or with DFMO (▲, 100 
µM for myeloma cells, 500 µM for LN229 and 1 mM for COS7 cells) for the indicated times; D, 
Time-dependent inhibition of primary cultures of human aortic smooth muscle cells (■), of LN18 (▲), 
NIH3T3 (●) and Jurkat (▼) cells, subjected to 100 µM POB. Error bars represent the standard 
deviation. 
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Figure 6.  Dose dependent cell growth inhibition by POB and DFMO. Glioma LN229 cells were 
incubated with different concentrations of POB (■) or with DFMO (□) for 5 days, counted (–––) and 
compared with the untreated controls. For measuring [3H]dThd incorporation (- - -), LN229 cells were 
incubated with [3H]dThd for 15 hours after 2 days pretreatment with POB (●) or DFMO (○). Error bars 
represent the standard deviation. 
 
Treatment of cells with POB affects the morphology of cells in different ways. Only 
few dead cells were found in untreated LN229 cells but a high fraction of cells 
detached after treatment with POB (100 µM) for 3 days. DFMO-treated (500 µM) 
LN229 cells showed higher cell density with less detached cells (Supplementary Fig. 
S3A). The number of detached cells after POB treatment seemed to depend on the 
dose of POB. If COS7 cells were treated with POB, many cells died and detached 
(round floating cells) and a substantial percentage (~40%) of attached COS7 cells 
could be stained with trypan blue indicating dying cells (Supplementary Fig. S3B). 
Only few dead cells were found among untreated attached COS7 cells if stained with 
trypan blue (data not shown). SW2 cells tend to aggregate and form large clumps. As 
shown by the inhibition of DNA synthesis, treatment with POB inhibited cell 
proliferation of SW2 and substantially decreased the size and amount of cell 
aggregates (Supplementary Fig. S3C). The microscopic cell images indicate that 
inhibition of ODC arrested cell proliferation that is followed by cell death. The 
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change in morphology of cells might reflect the importance of ODC activity for 
maintaining the cell shape (28, 29). 
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2.5 Discussion 
 
The present study describes the successful action of POB, a newly developed inhibitor 
of ODC, on various tumor cells. The development strategy bases on the external 
aldimine, an obligatory intermediate in the mechanism of action of ODC. In the 
pyridoxyl-ornithine derivative POB, the 5’-phosphate group is eliminated and the 
carboxyl group is esterified with methanol. The rationale behind the design was that 
this compound together with the additional hydrophobic BOC group of the ε-amino 
group of ornithine has no negative net charge and very likely crosses the cell 
membrane as it was reported for several pyridoxyl-amines (30, 31) and 
pyridoxyl-methionine analogs (32). Intracellular pyridoxal kinase, an enzyme that 
seems to tolerate considerable variation in C4’ position of the pyridoxyl moiety (31, 
33) is expected to phosphorylate this compound after it has been taken up by the cells 
whereas the carboxymethyl ester will be hydrolyzed intracellularly. The 
phosphopyridoxyl-ornithine analog formed in cells will bind with very high affinity to 
the newly synthesized apoornithine decarboxylase and affecting only proliferating 
cells in which ODC is obligatory induced.  
  POB, the synthesized precursor of a covalent coenzyme-substrate adduct of ODC is 
taken up by the cells. Intracellularly, the compound is transformed and binds as 
deduced and demonstrated by the inhibition of ODC activity to newly synthesized 
ODC. The response time of POB varied in different cell lines; with LN229 cells a lag 
of more than one day had been observed. The delayed inhibition might be due to the 
necessary transformation, i.e. ester hydrolysis and phosphorylation (as discussed 
above) of POB to an efficient ligand of ODC, processes that might well vary in 
different cells. Additionally, one has to consider that the active compound has to 
compete with intracellular pyridoxal phosphate (∼ 20 to 50 µM (34)), a necessity for a 
cell to survive. Although the prominent ODC inhibitor DFMO acts directly with 
active ODC, less pronounced growth inhibition effects were observed even at higher 
concentrations of DFMO. The treatment of cells with POB does neither up-regulate 
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nor down-regulate significantly ODC expression whereas an up-regulation was 
reported with DFMO (5) and was also observed in our hand (Supplementary Fig. S2). 
  Consistent with the inhibition of ODC activity by POB is the inhibition of cell 
proliferation in the investigated tumor cells. Again, cells respond differently on dose 
and time of exposure to POB. The IC50 of POB is, under serum culture condition, in 
the µM-range (50 µM for LN229). Myeloma cells respond immediately, and COS7 or 
LN229 cells stopped cell proliferation after exposing them to POB for one to two days, 
whereas human aortic smooth muscle cells are not affected significantly by POB.   
  The proposed strategy suggests that the intracellularly transformed POB derivative 
binds most likely only to newly synthesized apo-ODC since competing bound PLP 
out of holo-ODC might be very unlikely to happen in the short life cycle of ODC due 
to the intrinsic high affinity of PLP. In addition to that, the transformed POB 
derivative seems to bind specifically ODC and does not inhibit human histidine 
decarboxylase another highly induced PLP dependent enzyme in cells (data not 
show). 
   DFMO, however, will interact only with active ODC. Adding POB or DFMO to 
cell extracts and measuring subsequently ODC activity showed indeed that DFMO 
(500 µM) inhibited ODC activity whereas POB (100 µM) had only a minor effect 
(data not shown). Although DFMO was able to suppress the activity of ODC in vitro 
and in cells, it was less efficient in preventing cancer cell proliferation. This indicates 
a different mechanism of action of these two inhibitors in inhibiting cell proliferation. 
This conclusion is further supported by the observation that cells supplied with excess 
of polyamines in culture medium responded differently if treated with POB or DFMO, 
respectively. The inhibition of DFMO-treated cells was reversed by addition of 
polyamines (Fig. S4), an already well-known effect (35, 36). Conversely, POB treated 
cells did not show much differences in the presence or absence of additional 
polyamines (Fig. S4).  
  This different behaviour could be explained by the observed intracellular 
polyamine pool. In POB treated cells putrescine declined at most after two days, when 
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the inhibition of ODC caused by POB became effective (Fig. S5 and 3B). However 
the polyamine level is not lower than that of the controls, whereas DFMO was 
reported to deplete the PUT, SPD, but not SPM pool already after a day (37) and was 
also observed in our hand with LN229 that were treated with 500 µM DFMO for two 
days ( PUT: 0.09, SPD: 0.06, SPM: 2.5 nmol/106 cells). This clearly indicates that the 
inhibitory action caused by POB is different from that of DFMO, and is not simply 
caused by PUT and SPD depletion. Possible explanations could be that 
POB-derivatives might act as a kind of polyamine analogue and interfere with the 
polyamine conversion (as indicated by a two-fold increase of polyamine oxidase 
activity, see Fig. S6) and transport, a complex interplay whose regulation is not yet 
understood (23, 38, 39). 
  Modeling the inhibitor into the active site of hODC revealed a relatively large 
hydrophobic pocket formed by the two subunits of hODC at the position of the 
ε-amino group of ornithine suggesting to us not to remove the BOC-protecting group 
of POB (Fig. 1B). And indeed, the BOC group contributes substantially to the 
successful inhibitions as we could not find a comparable inhibition if it was removed. 
Besides the favourable binding suggested from the molecular modeling experiment, 
the improved bioavailability might also contribute to the efficiency of POB. The 
calculated logP (Log octanol/water partition coefficient, which is a theoretical tool for 
measuring the lipophilicity of a compound) of POB is 1.72 and without the BOC 
group -0.50 (calculated values were obtained from www.logp.com), which is a very 
strong indication that POB can more efficiently cross the cell membrane (40).  
  The attempt to develop a cell growth inhibitor by targeting ODC was successful 
and proved the proposed strategy. The newly designed and synthesized transition 
state-based analog (POB) was very effective in inhibiting newly induced cellular 
ODC activity and exceeded the potency of DFMO, the best and well characterized 
inhibitor of ODC so far, in inhibiting proliferation of many types of tumor cells. POB 
inhibits the proliferation of broad variety of tumor cell lines, such as myeloma, glioma 
LN18 and LN229, Jurkat, COS7 and SW2 cells, but not the non-tumorigenic human 
aortic smooth muscle cells. Glioblastoma multiforme (GBM) is the most aggressive 
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form of primary brain tumors known collectively as gliomas. Very few therapeutic 
options exist for the treatment of human glioblastoma (41). Here we report that POB 
can suppress the proliferation of low grade (IC50 ~50 µM) but also high grade 
glioblastoma cells (GBM). Future experiments will have to show whether the 
promising results with POB in culture studies can be confirmed in animal or even 
clinical studies. Structure modification of this inhibitor might improve its action and 
can be proposed and performed on the basis of the interaction model of POB with 
ODC. 
   
  In conclusion, the present study demonstrates that selected PLP-dependent enzymes 
in cells can be targeted with the proposed transition state-based inhibitors and the 
designed strategy might serve to develop inhibitors of this type for other 
PLP-dependent enzymes of pharmacological interest. 
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2.8 Supplemental Data 
 
Figure S1.  Nanoelectrospray Mass Spectra of POB. 
 
 
 
 
 
Figure S2.  Western blot analysis of ODC after treatment of COS7 cells with POB 
(100 µM) and DFMO (500 µM) for 2 days. Cells were then collected and lysed. Two 
fold Laemmli buffer was added to aliquots of the supernatant. The same amount (20 
µg) of total proteins was subjected to SDS-PAGE. The main band around 53 KD 
represents ODC.  
ODC
Control DFMO POB  
                100%   160%       70% 
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Figure S3. Cell morphology and cell culture images. A, LN229 cells were treated 
with POB (100 µM) or DFMO (500 µM) for 3 days. B, COS7 cells were treated with 
POB (100 µM) for 2 days and stained with trypan blue. The black dots (right picture) 
indicated dead cells after trypan blue staining. Bar, 50 µm. C, SW2 cells were treated 
with POB (100 µM) for one day. Images from culture plates were made with an 
NIKON inverse light microscopy. 
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Figure S4. Effect of added polyamines on cell growth inhibition caused by POB 
or DFMO. LN229 cells were and treated as indicated in the figure for 4 days in the 
presence of 2 mM aminoguanidine (an inhibitor of serum oxidase). Error bars 
represent the standard deviation. 
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Figure S5. Polyamine contents in LN229 cells. LN229 cells were treated without (o) 
or with POB (■, 100 µM) for the indicated days. Cultures were then harvested and 
acid-soluble polyamine and cell number were determined as indicated in the Materials 
and Methods. Error bars represent the standard deviation. 
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Figure S6. Induction of polyamine oxidase activity by POB. LN229 cells were 
treated with inhibitors (indicated in the figure) or without treatment (100%) for two 
days. Then cells were collected, lysed and polyamine oxidase acivity was measured as 
described in the Materials and Methods. 
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3. Structural requirements for novel coenzyme-substrate 
derivatives to inhibit intracellular ornithine decarboxylase and 
cell proliferation 
Fang Wu, Lo Persson and Heinz Gehring 
3.1 Abstract:  
Transition-state-based inhibitors bind with high affinity to their target enzymes. 
Mimics of a transition-state intermediate of pyridoxal 5’-phosphate-dependent 
enzymic reactions were used to study the structural requirements for optimal 
inhibition of intracellular ornithine decarboxylase and proliferation of tumor cells. 
Previously, we had developed such a coenzyme-substrate analog (POB) as a new 
inhibitor of the short-lived inducible intracellular human ornithine decarboxylase 
(ODC). In the present study, structurally diverse enzyme-substrate mimics were 
designed, synthesized and tested for their inhibitory potential. Out of 23 conjugates, 
phosphopyridoxyl- and pyridoxyl-tryptophan methyl ester (pPTME, PTME) proved 
significantly more potent in proliferation inhibition of LN229 cells than POB, and 
particularly more than alpha-DL-difluoromethylornithine, a medically used 
irreversible inhibitor of ODC. All the active compounds have a hydrophobic side 
chain fragment and a kind of polyamine motif (-NH-(CHX)4-NH-). As predicted from 
the molecular modeling results, the binding affinity of pPTME and PTME was higher 
than that of POB. Phosphorylated pPTME and PTME strongly inhibited intracellular 
ODC activity of LN229 cells at a concentration of 50 µM and 100 µM, respectively. 
PTME, pPTME and POB induce, as polyamine analogs do, the activity of the 
enzymes of the polyamine catabolism, polyamine oxidase and spermine/spermidine 
N1-acetyltransferase, up to 250% and 780%, respectively. The dual mode of these 
compounds in LN229 cells, i.e. inhibition of ODC and induction of polyamine 
catabolic enzymes, influences the intracellular polyamine pools and might underlie 
their inhibitory effect on cell proliferation that compares favorably with that of 
difluoromethylornithine.   
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3.2 Introduction 
 
  Polyamine (PA) metabolism is closely linked to cancer and other hyperproliferative 
diseases and offers numerous potential targets for anti-cancer or chemopreventive 
agents (1). Biosynthesis, catabolism and transport of PAs interplay in a complex 
system still not fully understood (2). Ornithine decarboxylase (ODC), catalyzes the 
first and rate-limiting step in PA biosynthesis converting ornithine into putrescine 
(PUT) and is a highly inducible pyridoxal 5’-phosphate (PLP)-dependent enzyme 
with a half life of only 20 ~ 60 min (3). PUT is further transformed into spermidine 
(SPD) and SPD into spermine (SPM), the multi-charged PAs, by spermine/spermidine 
synthase, respectively (2, 4). Spermine/spermidine N1-acetyltransferase (SSAT) and 
polyamine oxidase (PAO) are inducible enzymes of the PA catabolism and produce 
PUT or SPD in a two-step process from SPD or SPM, respectively (1). Cells are also 
able to import and export PAs by an ATP-dependent and selective PA transporter, 
which is still not well characterized (3, 5). 
ODC expression is rapidly induced after exposing cells with cell 
proliferation-stimulating agents (6-8). High levels of ODC observed in cancer cells 
are closely related to tumor promotion (3, 9). Overexpression of ODC induces 
transformation of cells (10) and inhibition of ODC abolishes transformation and is 
associated with tumor suppression (6, 11). Even modest reductions in ODC activity 
can lead to markedly reduced tumor development (6, 11). ODC-overexpressing cells 
are tumorigenic and expression of ODC in hair follicle cells is linked to growth and 
maintenance of hair follicles (12). Thus, ODC is a target in the development of 
anti-proliferative agents (3, 6). The most widely used inhibitor of ODC is 
α-DL-difluoromethylornithine (DFMO). This enzyme-activated irreversible inhibitor 
efficiently depletes intracellular PUT and SPD (13). DFMO shows a beneficial 
selectivity against tumor over normal cells by targeting the overexpressed ODC (1). 
Clinical studies proved that DFMO is a well-tolerated agent but not as efficient, as 
initially thought, to treat cancer (1, 14, 15). Never the less, some positive results have 
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been achieved in recurrent anaplastic gliomas (16, 17). Synthetic PA mimics or 
analogs, as well as natural PA derivatives, also decrease tumor cell growth rapidly 
together with or without depletion of intracellular PA pools (2, 18). In contrast to 
DFMO, these agents strongly induce the activity of SSAT and PAO, the polyamine 
catabolic enzymes, and downregulate ODC by a cellular feedback mechanism without 
directly inhibiting ODC activity (1). Different derivatives of SPD and SPM are 
currently in pre-clinical or clinical studies be it as a single agent or in combination 
with other drugs (3). However, they seem to exert, like SPM, unacceptable toxicities 
(1, 3). Therefore, novel types of inhibitors acting in the PA metabolism, which 
overcome or diminish these problems are in high demand.  
   Creating mimics of transition-state intermediates of enzymic reactions is a 
powerful strategy in developing potent and specific inhibitors for enzymes (19, 20). 
PLP is the cofactor of vitamin B6-dependent enzymes, which catalyze a wide variety 
of amino acid transformations (21, 22). PLP binds with high affinity (Km ~ 90 nM) to 
rat ODC (23). An obligatory step in all these reactions is the intermediary formation 
of an aldimine, i.e., a Schiff base of PLP with the α-amino group of the amino acid 
substrate. Reduction of the aldimine double bond produces phosphopyridoxyl-amino 
acids, which are analogs of the covalent coenzyme-substrate adducts. These 
compounds are a kind of transition-state analogs that bind to the apoprotein with high 
affinity (24-26). They cannot be transformed by the enzymes and thus inhibit them 
very potently. A further advantage of these analogs of coenzyme-substrate adducts is 
the high degree of specificity for the corresponding apoenzyme (25, 27, 28). 
   Based on this knowledge, we recently developed a strategy to deliver such a 
Schiff base analog as bioavailable prodrug for intracellular ODC (27). The precursor 
inhibitor POB, a pyridoxyl-ornithine methyl ester conjugate, which was taken up by 
cells and assumed to be phosphorylated by intracellular pyridoxal kinase (29, 30), 
efficiently suppressed ornithine decarboxylase activity in cells and the proliferation of 
many types of tumor cell lines with a better efficiency than DFMO, the most widely 
used inhibitor of ODC, and without affecting the proliferation of human 
non-tumorigenic smooth muscle cells (27). The inhibitory action caused by POB 
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(pyridoxyl-ornithine(BOC)-OMe, compound 14 in Figure 1) is different from that of 
DFMO, and it seems that POB-derivatives might act as a kind of PA analog and 
interfere with the PA conversion and transport, a complex interplay, whose regulation 
is not yet understood (31-33). 
   To improve the inhibitory effect of this kind of inhibitors of intracellular hODC, 
the structural requirements for binding to and inhibiting hODC and for inhibiting cell 
proliferation were investigated. Based on the structural model described previously 
(27), various structurally diverse conjugates of pyridoxal (PL) or PLP and substrate or 
PA analogs were synthesized and tested as potentially improved inhibitors and/or as 
inactive analogs to explore the mode of action of these compounds. Only compounds 
that have a hydrophobic side chain and a motif of PA inhibited the activity of 
intracellular ODC, induced the SSAT and PAO activity, the intracellular PA catabolic 
enzymes, and suppressed the proliferation of LN229 cells.  
 
     
3.3 Materials and Methods 
 
Materials   
Compounds 1 to 3 (tyrosine, alanine and lysine analogs) were kind gifts from Dr. P. 
Christen (Department of Biochemistry, University Zurich) (34, 35). The starting 
materials for synthesis of other compounds (Figure 1), were bought from commercial 
sources: His-OMe·2HCl from Bachem (Bubendorf, Switzerland) for compounds 4 
and 9; His·HCl (Sigma, Missouri, USA), 5; His(1-Me)-OMe His·HCl (Bachem), 6; 
histamine·2HCl (Sigma), 7 and 8; Trp-OMe·HCl (Bachem), 10 to 13; 
Orn(BOC)-OMe·HCl (BOM, Bachem), 14 and 15; Phe-OMe·HCl (Bachem), 16; 
ß-(3-pyridyl)-D-Ala-OMe·2 HCl (Bachem), 17; α,γ-diaminobutyric 
acid(Boc)-OMe·HCl (Bachem), 18 and 19; putrescine·2HCl (Fluka, Buchs, 
Switzerland) for 20, spermidine·3HCl (Fluka) for 21 and 23, and spermine·4HCl 
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(Fluka) for 22. Compounds 11, 13, 15 and 19 were hydrolyzed by-products generated 
during synthesis. Protease inhibitors were obtained from Roche (Basel, Switzerland). 
L-[1-14C]Acetyl CoA (55 mCi/mmol) and L-[1-14C]ornithine (55 mCi/mmol) were 
from American Radiolabeled Chemicals Inc (Missouri, USA). Pyridoxal·HCl and 
pyridoxal 5’-phosphate were purchased from Fluka, pyridoxamine 5’-phosphate and 
aminoguanidine dicarbonate from Sigma, and BOC-protected lysine methyl ester 
(BOL; from Bachem). 
 
Procedure for synthesis 
Compounds 4 to 7, 9 to 13 and 20 to 23 (Figure 1) were synthesized as described (36). 
Briefly, PL or PLP (1 mmol) and NaHCO3 (2 mmol) were dissolved in 5 ml ethanol 
and the substrate analogs (1.05 mmol) together with NaHCO3 (3 mmol) in 10 ml 
ethanol. Both solutions were mixed at 0 ºC and stirred at room temperature for 2 h. 
NaBH4 (125 mg) was then added in small portions to the solution on ice. After 30 min 
acetic acid (100%) was added to pH 5 to stop the reaction. The solvents were removed 
with a vacuum dryer; the residue was dissolved in water and subjected to FPLC or 
HPLC for analysis and purification. Compounds 15 to 19 were synthesized as 
described for POB (compound 14, see ref. 27). Compound 8 was obtained according 
to procedures described (37). Briefly, histamine (1.02 mmol) and KOH (4.2 mmol) 
was dissolved in 2.5 mL water and stirred at 0 °C for 10 min. Solid PL (1 mmol) was 
then added followed by ethanol (20 ml). The reaction mixture was stirred at 30 °C for 
7 h and the solvent evaporated, yielding a white powder.  
  Compound 4 to 9 and 20 to 23 were analyzed and purified with FPLC equipped 
with a mono S HR5/5 column (Amersham pharmacia biotech, Sweden) and a 
multiwavelengh detector. The samples were loaded and separated with a flow rate of 
0.5 ml/min using the following elution steps: 0-5 min, 100% solvent A (50 mM acetic 
acid pH 4.6) and 0% solvent B (50 mM acetic acid, pH 4.6, 1 M NaCl); 5-30 min, 
0-100% B; 30-40 min, 100% B. Detection was at 290 nm. Compounds 10 to 19 were 
analyzed and purified with a Kromasil C18 column (4.6 × 250 mm; Akzo Nobel, 
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Sweden). The samples were loaded and separated with a flow rate of 0.15 ml/min 
using the following elution steps: 0-36 min, 100% solvent A (3% acetonitrile/0.1% 
TFA) and 0% solvent B (80% acetonitrile/0.1% TFA); 36-92 min, 0-80% B; 92-120 
min, 80-100% B, followed by 100% B. Elution was recorded at 290 nm. A preparative 
Kromasil C18 column (50.8 × 250 mm; Akzo Nobel, Sweden) with a flow rate of 15 
ml/min was used under the same conditions to prepare larger amounts of compounds. 
The purified compounds (purity >95%) were analyzed and verified by ESI-MS and 
ESI-MS-MS. All compounds were vacuum-dried several times after adding water and 
stored at a concentration of about 10 mM (aqueous stock solution) at –20 °C. 
 
Cell culture  
Glioma cell line LN229 (from brain) was a generous gift from Dr. K. Frei 
(Department of Neurosurgery, University Hospital Zurich). LN229 cells were 
maintained in DMEM supplemented with 1 g/L glucose, 10% FBS (Life 
Technologies), 20 µg/ml gentamycine (Fluka) in a humidified 5% CO2 atmosphere at 
37 °C. HMC-1 (a human mastocytoma cell line) cells were a generous gift from Dr J. 
Butterfield (Mayo Clinic, Rochester, Minn, USA) and maintained in Iscove's modified 
DMEM supplemented with 10% FBS in a humidified 5% CO2 atmosphere at 37 °C. 
For measuring cell growth, cells were seeded (2.5 - 5 x 104 cells per well) and 
incubated in 0.5 ml medium containing 5% FBS or NBCS and 1% 
penicillin/streptomycin in 24-well plate. After one day, cells were incubated for the 
indicated times in the absence or presence of the compounds at the indicated 
concentrations. Cells were counted with a Coulter counter (ZM Coulter Electronics) 
as described (38). 
 
Enzyme activities 
ODC activity was measured by the released 14CO2 from L-[1-14C]ornithine as 
described (27). Polyamine oxidase activity was determined as described (31). LN229 
cells were seeded in 6-well plates at a density of ~1.6 x 105 cells per well with 5% 
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FBS for one day and treated in the absence or presence of the indicated compound 
during 2 days. Cells were then lysed and polyamine oxidase activities measured. 
SSAT activity was determined essentially according to a published procedure (39). 
LN229 cells were seeded in 6-well plates at a density of ~1.6 x 105 cells per well with 
5% FBS for one day and treated in the absence or presence of the indicated compound 
during 2 days. Cells were then lysed in 50 mM Tris-HCl (pH 7.8) by two cycles of 
freezing (liquid nitrogen) and thawing (37 °C, 2 min). After centrifugation, the 
supernatants (70 µL) were incubated with 0.4 µCi [14C]acetyl-CoA and unlabeled 
spermidine (3 mM) for 15 min. 
 
Molecular modeling 
Modeling of phosphopyridoxyl conjugates into the active site of hODC was 
performed as described (27) for POB (Figure 1, 14). 
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Fig. 1 Chemical structure of designed pyridoxyl-substrate derivatives.  
The compounds were synthesized, purified and verified by ESI-MS methods as 
described in Materials and Methods. MSa: theoretical mass. MSb: measured mass 
[M+H] +.  
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3.4 Results and Discussion 
 
Inhibiting proliferation of tumor cells and cellular hODC 
   As demonstrated previously (27), a hydrophobic pocket is present at the active site 
of hODC, where the ε-amino group of ornithine is embedded between the two hODC 
subunits. The pocket is formed by the aromatic residues TyrA389, TyrA331, PheB397, 
and TyrB323. Only the dimer of ODC is catalytically active, as an active site consists 
of residues from both subunit A and B. This hydrophobic pocket is not occupied by 
the substrate ornithine (27) and can be utilized in designing hydrophobic derivatives 
of inhibitors with improved binding affinity. Indeed, this pocket favored the binding 
of the leading compound POB which carried a BOC group at the ε-amino group. Here 
we conjugated PL or PLP with different amino acid derivatives or PAs (1 to 23, Figure 
1). As shown in Figure 2A, DFMO, the synthesized and purified (see Materials and 
Methods) vitamin B6 conjugates 1 to 23 (Figure 1), the PAs (PUT, SPD, SPM) and the 
cellular active forms of vitamin B6 (PL, PMP or PLP) as well as amino acid 
derivatives (BOM and BLM) were screened for their property to prevent proliferation 
of LN229 cells. Only the compounds 10, 12, 14, 16 and 17 which contain a 
hydrophobic amino acid side chain such an aromatic ring or a BOC group together 
with a methyl ester at the α-carboxylate group inhibited proliferation of LN229 cell at 
100 µM concentration more or equally efficiently than DFMO at 500 µM 
concentration. Cell inhibition was totally abolished, if the side chain of the conjugate 
was positively (4-9 and 20-23) or negatively charged (3) (Figure 2A). The 
de-esterified forms (11, 13, and 15) of compound 10, 12 and 14 also lost the inhibitory 
effect. Thus, a bulky hydrophobic group in the side chain favors the binding to ODC 
and the methyl esterification seems to be crucial for uptake into cells (27). 
   In agreement with their inhibitory effect on cell proliferation inhibition, 
pyridoxyl- and phosphopyridoxyl-L-tryptophan methyl ester (PTME, 10 and pPTME, 
12), the BOC-protected pyridoxyl-L-ornithine methyl ester (POB, 14) and the 
pyridoxyl-L-phenylalanine methyl ester (16) also significantly affected serum-induced 
intracellular ODC activity, while conjugates with an imidazole motif (4-6), pyridine 
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D-alanine methyl ester (17) or BOC-protected α, γ-diaminobutyric acid methyl ester 
(18) did not (Figure 2B). Phosphorylated PTME (12) suppressed the induced 
intracellular ODC activity nearly completely if LN229 cells were treated at a 
concentration of 50 µM for 3 days, an inhibition comparable to that with PTME (10) 
and POB (14) at 100 µM (Figure 2B). The pPTME and 
phosphopyridoxyl-L-tryptophan (13, Figure 1), that is the cellular active form of 
pPTME and PTME, were found to inhibit the ODC activity in LN229 cell extracts 
with an IC50 ~ 50 µM, whereas unphosphorylated PTME, POB, 16 and 17 as well as 
compound 18 did not. The simple conjugates pyridoxyl-ornithine and 
pyridoxyl-lysine failed to inhibit cell proliferation and the activity of ODC in vitro (25) 
as we observed with pyridoxyl-putrescine (20, Figure 1 and Figure 2A). 
  The inhibition of cell proliferation and ODC activity by compounds bearing an 
ornithine-like side chain with a -NH-(CHx)4-NH- motif (10, 12 and 14) was more 
pronounced than that of compounds lacking the distal N atom in the side chain (16) or 
having it in the wrong position (18 and 19). Compound 18, a mimic of POB, was 
synthesized as a control compound. It has a hydrophobic BOC group but one 
methylene group less and a -NH-(CH2)3-NH- motif instead of the -NH-(CHx)4-NH- 
PA motif. The missing inhibition of hODC and cell proliferation of the various 
compounds (Figure 2) strongly indicates that the inhibitory effect of POB, pPTME 
and PTME is due to quite specific interactions. Pyridoxyl-L-lysine, with a 
-NH-(CH2)5-NH- motif, is not an inhibitor of hODC in vitro either, as reported (25). 
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Fig. 2 Effect of pyridoxyl-substrate derivatives on cells.  
A) Effect on cell proliferation. Glioma LN229 cells were treated for 3 days with the indicated 
compounds. DFMO, α-DL-difluoromethylornithine; compounds 1 to 23 (Fig. 1); PUT, putrescine; SPD, 
spermidine; SPM, spermine; PL, pyridoxal; PMP, pyridoxamine 5’-phosphate; PLP, pyridoxal 
5’-phosphate; BOM, BOC-protected ornithine methyl ester and BLM, BOC- protected lysine methyl 
ester. The concentration used was 100 µM except for DFMO (500 µM), compound 12 (50 µM), PLP, 
BOM and BOL (200 µM each). Cells were counted as described in Materials and Methods. Error bars 
represent the standard deviation (n=3). To prevent exogenous oxidation of PUT, SPD and SPM, 2 mM 
aminoguanidine was added to inhibit serum oxidases. 
B) Effect on serum-induced intracellular ODC activity. LN229 cells were treated with the indicated 
compounds for 3 days. Cells were collected, lysed and ODC activity was measured as described in 
Materials and Methods. Error bars represent the standard deviation (n=3).  
   
Compounds 
  Compounds 
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The conjugate of pyridoxal with pyridyl-D-alanine methyl ester (17), which has a 
-NH-(CHx)4-NH- motif and a hydrophobic side chain but a D instead of a L chiral 
centre, showed no inhibition of hODC activity in cells and in cell extracts. These 
results demonstrate that maintaining the -NH-(CHx)4-NH- motif of the L-ornithine 
backbone is essential for binding to ODC and that additional hydrophobic 
modifications at the ε-amino group of ornithine or appropriate bulky hydrophobic side 
chains increase the binding affinity. PTME and pPTME (10 and 12) were the most 
potent inhibitors of cell proliferation of LN229 cells (Figure 1) with an IC50 value ~ 
25 µM and ~ 50 µM, respectively (Figure 3). The phosphorylated PTME exceeded the 
potency of POB, the previously reported leading compound 14 (27), due to better 
binding properties and uptake kineticses, indicated by an earlier cell growth arrest of 
pPTME and PTME than with POB. After a one-day treatment, the inhibition was 
already comparable to that of POB after two-days (data not shown). 
   
Fig. 3 Dose-dependent cell growth inhibition by PTME (10) and pPTME (12). 
Glioma LN229 cells were incubated with different concentrations of PTME (●) or 
with pPTME (■) for 3 days, counted and compared with the untreated controls (0%). 
Error bars represent the standard deviation (n=3).  
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Binding mode of designed compounds  
   The presumably active form of PTME (10) and pPTME (12) in the cell is 
phosphopyridoxyl-tryptophan (13, Figure 1). A binding model of compound 13 was 
constructed by molecular modeling (see Materials and Methods, Figure 4A). It 
showed a tight interaction with hODC. The side chain of tryptophan is embedded in a 
hydrophobic pocket composed of resides TyrA331, TyrA389, TyrB323 and PheB397, 
and binding is supported by stacking effects between the aromatic rings of the indole 
(white in Figure 4A) and tyrosine TyrA389. The N atom of the indole ring is able to 
form a hydrogen bond with the Asp332 (Figure 4A), which is situated at the entrance 
of the hydrophobic pocket and normally interacts with the ε-amino group of ornithine 
(40). The presumed intracellular forms of the inactive compounds 17 and 18 cannot 
properly occupy the cofactor or substrate binding site and lack the favorable 
interactions (Figure 4B, red and brown). The substantial loss of affinity of compound 
4 with an imidazole ring (cyan, Figure 4B) or of 16 with a bulky hydrophobic benzene 
ring (blue), could be due to the loss of this hydrogen bond and less pronounced 
hydrophobic interactions and ring stacking effect. 
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Fig. 4 Stereo view of the binding model of the phosphopyridoxyl conjugates in 
the active site of hODC 
A) The putative strong binding mode of phosphopyridoxyl (yellow)-tryptophan 
(white). The active site residues within 3 Å of the phosphopyridoxyl-tryptophan 
conjugate and the hydrogen bond between phosphopyridoxyl-tryptophan and Asp332 
are displayed in green. B) The putative binding mode of phosphopyridoxyl 
(yellow)-histidine (cyan), phosphopyridoxyl-phenylalanine (blue), phosphopyridoxyl 
-pyridine-D-Ala (red) and the BOC-protected phosphopyridoxyl -α,γ-diaminobutyric 
acid (brown). 
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Mode of action of the designed inhibitory compounds 
   DFMO, the suicide inhibitor of ODC, irreversibly binds to the active site of the 
holo enzyme by covalently attaching to Cys360. Cell inhibition caused by DFMO can 
be reversed by adding PAs to the cells (41). This effect was considered as one of the 
reason for the low efficiency of DFMO (3). PTME and pPTME (10 and 12) inhibited 
the proliferation of tumor cells more efficiently than DFMO but their inhibition of 
LN229 and HMC-1 cells could not be reversed by adding PAs (Figure 5) as was 
already observed and discussed with POB (27). This observation strongly indicates 
that pyridoxyl-amino acid derivatives inhibit cell growth not only by depletion of 
endogenous PAs but also by perturbing the complex PA metabolism in other ways. 
    
Fig. 5 Effect of exogenous polyamines on cell growth inhibition.  
LN229 cells were treated or not (control, 100%) as indicated during 3 days in the 
presence of 2 mM aminoguanidine, which inhibits the oxidation of polyamines by 
serum oxidases. White column, LN229 cells; Black column, HMC-1 cells. Error bars 
represent the standard deviation (n=3). 
    
  PA analogs strongly induce the catabolic enzymes SSAT and PAO of PA 
metabolism by acting in a complex PA regulatory system (42, 43) and stop cell 
proliferation with or without depleting the PA pools (2, 18). POB suppressed the 
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proliferation of many types of tumor cells without depleting the intracellular PA pools 
more than in the control (27). PTME and pPTME inhibited cell growth more strongly 
than POB and did also not deplete intracellular PA. The putrescine, spermidine and 
spermine concentration in LN229 cells treated with 100 µM PTME for 3 days, were 
0.4, 2.7 and 3.6 nmol per 106 cells, respectively. The corresponding values for 
untreated LN229 cells were 0.2, 2.4 and 3.0 nmol per 106 cells, respectively. Reasons 
for maintaining the intracellular PA concentration could be that, despite the inhibition 
of intracellular ODC, the intracellular conversion of PAs is accelerated by PTME, 
pPTME and POB through enzyme induction. Indeed, intracellular PAO activity was 
upregulated to 195%, 270% and 206%, when LN229 cells were incubated for 2 days 
at the indicated concentrations of PTME, pPTME and POB, respectively (Figure 6A). 
DFMO (500 µM) and other conjugates had no effect. SSAT activity of LN229 cells, 
under the same conditions, was also induced to 620%, 790% and 194%, respectively, 
whereas DFMO had no such effect (Figure 6B).  Probably, the PA motif (-NH- 
(CHx)4 –NH-) present in PTME, pPTME and POB seems to be recognized by the PA 
regulatory system and thus induces the PA catabolic enzymes. The upregulation of PA 
catabolism might explain why this kind of inhibitors exert a more pronounced 
inhibition of cell growth than DFMO, which did not influence PAO and SSAT activity. 
Instead of only inhibiting intracellular hODC, these particular pyridoxyl-amino acid 
derivatives seem to act as PA analogs and induce SSAT and PAO. In the 
PAO-catalyzed reaction, H2O2 is produced, which is regarded as the main reason of 
cell death caused by PA analogs (1). The induced catabolism of PA regenerates PUT 
and SPD from SPD and SPM, respectively (44), and might explain why the PAs were 
not completely depleted even if ODC was inhibited. 
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Fig. 6 Effect of pyridoxyl-substrate derivatives on polyamine catabolic enzymes. 
LN229 cells were treated with the indicated compounds or not (control, 100%) for 
two days. Cells were collected, lysed and the activity of polyamine oxidase (A) or of 
spermine/spermidine N1-acetyltransferase (B) measured as described in the Materials 
and Methods. Error bars represent the standard deviation (for A, n=3; for B, n=2).  
 
Remarkably in this context is that the phosphorylated derivative of PTME 12 was 
able to inhibit intracellular ODC and cell proliferation, indicating that it is taken up by 
cells. Apparently, its hydrophobicity is such that it can pass the cell membrane. Its 
overall clogP of 1.1, which is in the range of cell-permeable compounds (45), and the 
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strong retardation of pPTME on a C18 column (eluted only with 100% solvent B, see 
Materials and Methods) support this conclusion. Because it is already phosphorylated, 
it will be more prone to bind to freshly synthesized apoODC than unphosphorylated 
conjugates, which have to be phosphorylated in cells by pyridoxal kinase. 
 In conclusion, the application of structurally diverse compounds to map the 
binding requirement of ODC proved an efficient tool to develop new inhibitors. ODC 
inhibitors of the kind presented in this study seem to be efficient agents for preventing 
proliferation of tumors cells. Besides ODC inhibition, the compounds PTME, pPTME 
and POB, which share the same PA motif (-NH-(CHx)4-NH-) (Figure 7), exert an 
additional effect, which seems to derive from mimicking PA by their ability to induce 
the PA catabolic enzymes SSAT and PAO. The overall action of these compounds on 
cells combines both, the effect of ODC inhibitors and that of PA analogs. In the search 
for alternative new therapeutic agents to treat malignant tumors such as gliomas the 
inhibitory pyridoxyl-derivatives as summarized and defined in Figure 7 could be used 
as lead compounds for developing even better inhibitors. 
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Fig. 7 Schematic representation of active inhibitors. 
Bold solid line, the required -N-(CHx)4-N- motif; bold dashed line, overlap of the 
skeleton of the hydrophobic fragments supporting binding. R1, moiety required for 
cell permeability.  
 
Structural requirements for novel coenzyme-substrate derivatives to inhibit hODC and cell proliferation      82 
 
3.5 Acknowledgment 
We acknowledge the financial support by COST Switzerland (Action 922, Grant 
number C02.0017). We thank Dr. S. Bienz and collaborators (Institute of Organic 
Chemistry, University Zurich) for the assistance in the synthesis of the designed 
analogs. Dr. K. Frei for kindly providing glioma cell lines, Dr. P. Christen 
(Department of Biochemistry, University Zurich) for providing us with some of the 
compounds and for critical reading of the manuscript, Dr. J. Butterfield and 
co-workers for providing HMC-1 cells, Dr. R. D. Walter and Dr. I. B. Müller for 
helpful discussions. 
Structural requirements for novel coenzyme-substrate derivatives to inhibit hODC and cell proliferation      83 
 
3.6 Reference 
1. Casero RA, Jr., Marton LJ. Targeting polyamine metabolism and function in 
cancer and other hyperproliferative diseases. Nat Rev Drug Discov 
2007;6:373-90. 
2. Wallace HM, Fraser AV, Hughes A. A perspective of polyamine metabolism. 
Biochem J 2003;376:1-14. 
3. Seiler N. Thirty years of polyamine-related approaches to cancer therapy. 
Retrospect and prospect. Part 1. Selective enzyme inhibitors. Curr Drug 
Targets 2003;4:537-64. 
4. Jackson LK, Brooks HB, Myers DP, Phillips MA. Ornithine decarboxylase 
promotes catalysis by binding the carboxylate in a buried pocket containing 
phenylalanine 397. Biochemistry 2003;42:2933-40. 
5. Igarashi K, Kashiwagi K. Polyamine transport in bacteria and yeast. Biochem 
J 1999;344 Pt 3:633-42. 
6. Pegg AE. Regulation of ornithine decarboxylase. J Biol Chem 
2006;281:14529-32. 
7. Nickel KP, Belury MA. Inositol hexaphosphate reduces 
12-O-tetradecanoylphorbol-13-acetate-induced ornithine decarboxylase 
independent of protein kinase C isoform expression in keratinocytes. Cancer 
Lett 1999;140:105-11. 
8. Glikman P, Manni A, Demers L, Bartholomew M. Polyamine involvement in 
the growth of hormone-responsive and -resistant human breast cancer cells in 
culture. Cancer Res 1989;49:1371-6. 
9. Gerner EW, Meyskens FL, Jr. Polyamines and cancer: old molecules, new 
understanding. Nat Rev Cancer 2004;4:781-92. 
10. Auvinen M, Paasinen A, Andersson LC, Holtta E. Ornithine decarboxylase 
activity is critical for cell transformation. Nature 1992;360:355-8. 
11. Nilsson JA, Keller UB, Baudino TA, et al. Targeting ornithine decarboxylase 
in Myc-induced lymphomagenesis prevents tumor formation. Cancer Cell 
2005;7:433-44. 
12. Wheeler DL, Ness KJ, Oberley TD, Verma AK. Inhibition of the development 
of metastatic squamous cell carcinoma in protein kinase C epsilon transgenic 
mice by alpha-difluoromethylornithine accompanied by marked hair follicle 
degeneration and hair loss. Cancer Res 2003;63:3037-42. 
13. Qu N, Ignatenko NA, Yamauchi P, et al. Inhibition of human ornithine 
decarboxylase activity by enantiomers of difluoromethylornithine. Biochem J 
2003;375:465-70. 
14. Messing E, Kim KM, Sharkey F, et al. Randomized prospective phase III trial 
of difluoromethylornithine vs placebo in preventing recurrence of completely 
resected low risk superficial bladder cancer. J Urol 2006;176:500-4. 
15. Vlastos AT, West LA, Atkinson EN, et al. Results of a phase II double-blinded 
randomized clinical trial of difluoromethylornithine for cervical intraepithelial 
neoplasia grades 2 to 3. Clin Cancer Res 2005;11:390-6. 
Structural requirements for novel coenzyme-substrate derivatives to inhibit hODC and cell proliferation      84 
 
16. Wallace HM, Fraser AV. Inhibitors of polyamine metabolism: review article. 
Amino Acids 2004;26:353-65. 
17. Levin VA, Hess KR, Choucair A, et al. Phase III randomized study of 
postradiotherapy chemotherapy with combination 
alpha-difluoromethylornithine-PCV versus PCV for anaplastic gliomas. Clin 
Cancer Res 2003;9:981-90. 
18. Fraser AV, Woster PM, Wallace HM. Induction of apoptosis in human 
leukaemic cells by IPENSpm, a novel polyamine analogue and anti-metabolite. 
Biochem J 2002;367:307-12. 
19. Li CM, Tyler PC, Furneaux RH, et al. Transition-state analogs as inhibitors of 
human and malarial hypoxanthine-guanine phosphoribosyltransferases. Nat 
Struct Biol 1999;6:582-7. 
20. Singh V, Evans GB, Lenz DH, et al. Femtomolar transition state analogue 
inhibitors of 5'-methylthioadenosine/S-adenosylhomocysteine nucleosidase 
from Escherichia coli. J Biol Chem 2005;280:18265-73. 
21. Eliot AC, Kirsch JF. Pyridoxal phosphate enzymes: mechanistic, structural, 
and evolutionary considerations. Annu Rev Biochem 2004;73:383-415. 
22. Christen P, Mehta PK. From cofactor to enzymes. The molecular evolution of 
pyridoxal-5'-phosphate-dependent enzymes. Chem Rec 2001;1:436-47. 
23. Flamigni F, Guarnieri C, Caldarera CM. Characterization of highly purified 
ornithine decarboxylase from rat heart. Biochim Biophys Acta 
1984;802:245-52. 
24. Raso V, Stollar BD. The antibody-enzyme analogy. Characterization of 
antibodies to phosphopyridoxyltyrosine derivatives. Biochemistry 
1975;14:584-91. 
25. Heller JS CE, Bussolotti DL, Coward JK. Potent inhibition of ornithine 
decarboxylase by N-(5'-phosphopyridoxyl)-ornithine. Biochim Biophys Acta 
1975;403:197-207. 
26. Khomutov RM, Dixon HB, Vdovina LV, et al. 
N-(5'-phosphopyridoxyl)glutamic acid and 
N-(5'-phosphopyridoxyl)-2-oxopyrrolidine-5-carboxylic acid and their action 
on the apoenzyme of aspartate aminotransferase. Biochem J 1971;124:99-106. 
27. Wu F, Grossenbacher D, Gehring H. New transition state-based inhibitor for 
human ornithine decarboxylase inhibits growth of tumor cells. Mol Cancer 
Ther 2007;6:1831-9. 
28. Wu F, Yu J, Gehring H. Inhibitory and structural studies of novel 
coenzyme-substrate analogs of human histidine decarboxylase. Submitted 
2007. 
29. Zhang ZM, McCormick DB. Uptake of N-(4'-pyridoxyl)amines and release of 
amines by renal cells: a model for transporter-enhanced delivery of bioactive 
compounds. Proc Natl Acad Sci U S A 1991;88:10407-10. 
30. Tang L, Li MH, Cao P, et al. Crystal structure of pyridoxal kinase in complex 
with roscovitine and derivatives. J Biol Chem 2005;280:31220-9. 
31. Dai H, Kramer DL, Yang C, et al. The polyamine oxidase inhibitor 
Structural requirements for novel coenzyme-substrate derivatives to inhibit hODC and cell proliferation      85 
 
MDL-72,527 selectively induces apoptosis of transformed hematopoietic cells 
through lysosomotropic effects. Cancer Res 1999;59:4944-54. 
32. Vujcic S, Halmekyto M, Diegelman P, et al. Effects of conditional 
overexpression of spermidine/spermine N1-acetyltransferase on polyamine 
pool dynamics, cell growth, and sensitivity to polyamine analogs. J Biol Chem 
2000;275:38319-28. 
33. Duranton B, Holl V, Schneider Y, et al. Cytotoxic effects of the polyamine 
oxidase inactivator MDL 72527 to two human colon carcinoma cell lines 
SW480 and SW620. Cell Biol Toxicol 2002;18:381-96. 
34. Gramatikova SI, Christen P. Pyridoxal 5'-phosphate-dependent catalytic 
antibody. J Biol Chem 1996;271:30583-6. 
35. Gramatikova S, Mouratou B, Stetefeld J, Mehta PK, Christen P. 
Pyridoxal-5'-phosphate-dependent catalytic antibodies. J Immunol Methods 
2002;269:99-110. 
36. Hidehiko KumagaI, Hideaki Yamada and Hiroshi Fukami. A Modified Method 
for Synthesis of Pyridoxylhistamine. Agr. Biol. Chem. 1969;33:1210-12. 
37. Kametani T, Koizumi M, Okui K, Nishii Y, Ono M. Biochemical studies on 
drugs and the central nervous system. 1. Synthesis and activity of pyridoxal 
derivatives. (Studies on the syntheses of heterocyclic compounds. 438). J Med 
Chem 1972;15:203-4. 
38. Geistlich A, Gehring H. CDGF (chicken embryo fibroblast-derived growth 
factor) is mitogenically related to TGF-beta and modulates PDGF, bFGF, and 
IGF-I action on sparse NIH/3T3 cells. Exp Cell Res 1993;204:329-35. 
39. Ulrich S, Loitsch SM, Rau O, et al. Peroxisome proliferator-activated receptor 
gamma as a molecular target of resveratrol-induced modulation of polyamine 
metabolism. Cancer Res 2006;66:7348-54. 
40. Jackson LK, Brooks HB, Osterman AL, Goldsmith EJ, Phillips MA. Altering 
the reaction specificity of eukaryotic ornithine decarboxylase. Biochemistry 
2000;39:11247-57. 
41. Wallick CJ, Gamper I, Thorne M, et al. Key role for p27Kip1, retinoblastoma 
protein Rb, and MYCN in polyamine inhibitor-induced G1 cell cycle arrest in 
MYCN-amplified human neuroblastoma cells. Oncogene 2005;24:5606-18. 
42. Pavlov V, Lin PK, Rodilla V. Biochemical effects and growth inhibition in 
MCF-7 cells caused by novel sulphonamido oxa-polyamine derivatives. Cell 
Mol Life Sci 2002;59:715-23. 
43. Vujcic S, Liang P, Diegelman P, Kramer DL, Porter CW. Genomic 
identification and biochemical characterization of the mammalian polyamine 
oxidase involved in polyamine back-conversion. Biochem J 2003;370:19-28. 
44. Casero RA, Jr., Pegg AE. Spermidine/spermine N1-acetyltransferase--the 
turning point in polyamine metabolism. Faseb J 1993;7:653-61. 
45. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and 
computational approaches to estimate solubility and permeability in drug 
discovery and development settings. Adv Drug Deliv Rev 2001;46:3-26. 
 
Inhibitory and structural studies of novel coenzyme-substrate analogs of hHDC                         86 
 
4.  Inhibitory and structural studies of novel 
coenzyme-substrate analogs of human histidine decarboxylase 
 
               Fang Wu, Jing Yu, Heinz Gehring  
 
4.1 ABSTRACT 
 
Histamine, a biogenic amine with important biological functions, is produced from 
histidine by histidine decarboxylase (HDC), a pyridoxal 5’-phosphate 
(PLP)-dependent enzyme. HDC is thus a potential target to attenuate histamine 
production in certain pathological states. Targeting mammalian HDC with novel 
inhibitors and elucidating the structural basis of their specificity for HDC are 
challenging tasks, because the 3D structure of mammalian HDC is still unknown. In 
the present study, we designed, synthesized and tested potentially 
membrane-permeable pyridoxyl-substrate conjugates as inhibitors for human HDC 
and modeled an active site of hHDC, which is compatible with the experimental data. 
The most potent inhibitory compound among 9 tested structural variants was the 
pyridoxyl-histidine methyl ester conjugate (PHME), indicating that the binding site of 
hHDC does not tolerate other groups than the imidazole side chain of histidine.  
PHME inhibited 60% of TPA-induced newly synthesized HDC in human HMC-1 
cells at 200 µM and was also inhibitory in cell extracts. The proposed model of hHDC, 
containing phosphopyridoxyl-histidine in the active site, revealed the binding 
specificity of HDC towards its substrate and the structure-activity relationship of the 
designed and investigated compounds. 
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4.2 INTRODUCTION 
 
The biogenic amine histamine plays an important role in a number of physiological 
processes, including inflammatory as well as allergic reactions, control of gastric acid 
secretion and neurotransmission (1-5). Histidine decarboxylase (HDC), a pyridoxal 
5’-phosphate (PLP) dependent homodimeric enzyme catalyzes the decarboxylation of 
histidine to histamine (Fig. 1) and is regarded as a potential target to attenuate 
histamine production in certain pathological states (3). 
 
 
 
Figure 1. Reaction mechanism of ODC with L-histidine. E-PLP, HDC-pyridoxal 
5’-phosphate (internal aldimine); ES-PLP, enzyme-coenzyme-substrate intermediate 
(external aldimine).  
 
Human HDC is initially translated as a 74 kD form and then post-translationally 
processed to the 53–55 kD form through a complex reaction, which is catalyzed by 
caspase-9 and cleaves off a C-terminal part (1). HDC shares high homology (51% 
identity) in primary sequence with dopa or aromatic acid decarboxylase (6). The 74 
kD form of HDC has a very low enzymic activity and is mainly recovered in the 
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insoluble fraction, whereas the 53-55 kD form is soluble and has a high activity if 
expressed in baculovirus-insect or mammalian cells (1). Endogenous hHDC is 
expressed only in histamine releasing cells such as mast cells, basophils, 
enterochromaffin-like cells in the stomach, neurons in the brain or macrophages (7). 
To date, the crystal structure of mammalian HDC is unknown due to its difficulties 
in preparation, heterogeneity and instability (3, 6). A structure of dimeric rat HDC 
with the cofactor PLP has been constructed by homology modeling using pig dopa 
decarboxylase (DDC) with the inhibitor carbiDOPA (Fig. 2A) as template (3, 6, 8). 
The proposed model contains no ligand, the interactions of binding-site residues of 
HDC with its ligands still being undefined.  
   Numerous inhibitors of mammalian HDC have been developed (9, 10). 
Alpha-fluoromethylhistidine (FMH), an enzyme-activated irreversible inhibitor of 
mammalian as well as pyruvoyl-dependent bacterial HDC, covalently attaches to 
active site residues after being activated by HDC itself, an inhibitory mechanism 
similar to α-DL-difluoromethylornithine, a suicide inhibitor of ornithine 
decarboxylase (11, 12).  Most other inhibitors are substrate analogs and inhibit the 
enzyme competitively. They have been developed in the seventies, by adding 
substituents to histidine in the hope to gaining additional affinity (13). However, the 
binding affinity did not improved much, with the methyl ester of histidine (HME, Fig. 
2A) being an exception (IC50 of  ~ 1.8 µM, in vitro). Unfortunately, HME proved to 
be inactive in cells, because it is hydrolysed to histidine, the substrate of HDC, after 
being taken up by cells (10). Bacterial pyruvoyl-dependent HDC was also reported to 
be inhibited by HME in vitro (10). Recently, (–)-epigallocatechin-3-gallate extracted 
from green tea was reported to inhibit rat HDC in vitro and in rat RBL-2H3 cells (14), 
but it also inhibited other PLP-dependent enzymes, such as ornithine decarboxylase 
(15).   
   Pyridoxal 5’-phosphate (PLP) is the cofactor for numerous enzymes, which 
catalyze a wide variety of amino acid transformations (16, 17). The external aldimine, 
a Schiff base of PLP with the α-amino group of the amino acid substrate (ES-PLP, 
Fig. 1), is the common intermediate of all transformation of amino acid catalyzed by 
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PLP-dependent enzymes (16). A stable analog of PLP-substrate adducts can be 
obtained by reduction of the Schiff base producing phosphopyridoxyl-amino acids. 
Such analogs of coenzyme-substrate adducts are, for obvious reasons, high-affinity 
inhibitors for PLP-dependent apoenzymes (18, 19). Based on the knowledge that such 
analogs strongly interact with the corresponding apoenzymes, we recently developed 
a strategy for delivering a novel Schiff base analog as inhibitor for intracellular 
PLP-dependent human ornithine decarboxylase. The inhibitor, a 
phosphopyridoxyl-ornithine based precursor (POB), efficiently suppressed ornithine 
decarboxylase activity in cells and also cell proliferation (20). 
To develop novel bioavailable inhibitors for mammalian HDC and explore their 
interaction with the active site of mammalian HDC, we designed and synthesized 
several pyridoxyl-amino acid-based precursor inhibitors for hHDC and deduced a 
structural model composed of PLP as well as histidine analogs in the active site of 
hHDC.  One of the designed compounds efficiently inhibited 
12-O-tetradecanoylphorbol-13-acetate (TPA)-induced hHDC activity in cells and in 
cell extracts without affecting human ornithine decarboxylase activity. The generated 
interaction model describes the structure-activity relationship of the tested compounds 
and of previously reported inhibitors. Moreover, it explains the binding specificity of 
mammalian HDC for histidine. 
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Figure 2. Chemical structure and inhibitory activity of various compounds. A) 
Substrate analogs of HDC and DDC. B) Designed and synthesized 
pyridoxyl-substrate analogs. The compounds 1 to 9 were synthesized, purified and 
verified as described in Materials and Methods. MSa: theoretical mass. MSb: 
measured mass [M+H] +. Inhibitiona: HMC-1 cells were pre-treated with the indicated 
compounds (150 µM) for 3 h, then incubated with 100 nM TPA for additional 3 h 
Inhibitory and structural studies of novel coenzyme-substrate analogs of hHDC                         91 
 
before cells were collected and lyzed. HDC activity was measured by trapping the 
released 14CO2 from L-[1-14C]histidine in assay buffer (see Materials and Methods). 
The inhibition values are expressed as the percentage of control (0%). Inhibitionb:  
HMC-1 cells were pre-treated with 100 nM TPA for 3 h, then lyzed, incubated with 
the indicated compounds (150 µM). HDC activity was measured as described 
(inhibition of control, 0%). The results are listed as the average ± stdev (n=3). 
 
 
4.3 MATERIALS AND METHODS 
 
Materials 
 
His·HCl and histamine·2HCl were bought from Sigma (Saint Louis, Missouri, USA). 
His-OMe·2HCl, His(1-Me)-OMe, Phe-OMe·HCl, ß-(3-pyridyl)-D-Ala-OMe·2 HCl, 
Trp-OMe·HCl, and α,γ-diaminobutyric acid(Boc)-OMe·HCl were from Bachem 
(Bubendorf, Switzerland). Protease inhibitors were obtained from Roche (Basel, 
Switzerland).  L-[1-14C]histidine (55 mCi/mmol) was from American Radiolabeled 
Chemicals Inc (Saint Louis, Missouri, USA). Pyridoxal·HCl and 
12-O-tetradecanoylphorbol-13-acetate (TPA) was from Fluka (Buchs, Switzerland). 
 
General procedure for synthesis of the compounds   
 
Compounds 1 to 6 (Fig. 2B) were synthesized as described for the synthesis of 
pyridoxylhistamine (21). Briefly, pyridoxal (1mmol) and NaHCO3 (2 mmol) were 
dissolved in 5 ml ethanol and the substrate analogs (1.05 mmol) together with 
NaHCO3 (3 mmol) in 10 ml ethanol. Both solutions were mixed at 0 ºC and stirred at 
room temperature for 2 h. Then, NaBH4 (125 mg) was added in small portions to the 
solution on ice. Acetic acid (100%) was added 30 min later to stop the reaction until 
pH 5 was reached. The solvents were removed with a vacuum dryer and the residues 
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were dissolved in water and subjected to FPLC or HPLC for purification and analysis. 
Compound 8 (Fig. 2B) was synthesized as reported previously for compound 7 (20). 
Compound 9 (cyclized form of compound 3) was obtained according to a reported 
procedure (22). Briefly, histamine (1.02 mmol) and KOH (4.2 mmol) were dissolved 
in water (2.5 ml) and stirred at 0 °C for 10 min. Then, solid pyridoxal (1 mmol) was 
added to the solution followed by ethanol (20 ml). The reaction mixture was stirred at 
30 °C for 7 h and the solvent evaporated, yielding a white powder.  
   Compounds 1, 2, 3 and 9 were analyzed and purified with FPLC equipped with a 
mono S HR5/5 column (Amersham pharmacia biotech, Sweden) and a 
multiwavelengh detector. The samples were loaded and separated with a flow rate of 
0.5 ml/min using the following gradient: 0-5 min, 100% solvent A (50 mM acetic acid 
pH 4.6) and 0% solvent B (50 mM acetic acid, pH 4.6, 1M NaCl); 5-30 min, 0-100% 
B; 30-40 min, 100% B. Detection was at 290 nm.  
   Compounds 4, 5, 6 and 8 were analyzed and purified with a HPLC equipped with 
a Kromasil C18 column (4.6 × 250 mm; Akzo Nobel, Sweden). The samples were 
loaded and separated with a flow rate of 0.15 ml/min using the following gradient: 
0-36 min, 100% solvent A (3% acetonitrile/0.1% TFA) and 0% solvent B (80% 
acetonitrile/0.1% TFA); 36-92 min, 0-80% B; 92-120 min, 80-100% B, followed by 
100% B. Elution was recorded at 290 nm. A preparative Kromasil C18 column (50.8 × 
250 mm; Akzo Nobel, Sweden) with a flow rate of 15 ml/min was used under the 
same conditions to prepare larger amounts of compounds. All compounds were 
vacuum-dried several times after adding water and stored at a concentration of about 
10 mM (water stock solution) at –20 °C. The obtained purified compounds (purity 
>95%) were analysed and verified by ESI-MS. 
   
Cell culture 
 
HMC-1 (a human mastocytoma cell line) cells were a generous gift from Dr J. 
Butterfield (Mayo Clinic, Rochester, Minn, USA) and maintained in Iscove's modified 
DMEM supplemented with 10% FBS in a humidified 5% CO2 atmosphere at 37 °C. 
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HDC activity 
 
HDC activity was measured by the released of 14CO2 from labeled histidine as 
described (2, 23, 24). For measuring TPA-induced HDC activity, cells were cultured 
in 6-well plate at a density of ~6 x 105 cells per well (2 ml) with 5% FBS for one day 
and then treated in the absence or in the presence of the indicated compound for 3 h. 
The cells were induced with 100 nM TPA for 3 h, collected and washed twice with 
ice-cold phosphate-buffered saline (PBS, pH 6.8). The collected cells were lyzed by 
freezing (liquid nitrogen) and thawing twice (37 °C, 2 min) in 310 µl lysis buffer (10 
µM EDTA, 10 µM PLP, 20 µM DTT and protease inhibitor cocktail in 100 mM PBS, 
pH 6.8). The reaction was started by adding 30 µl L-[1-14C]histidine (final 
concentration, 130 µM; 0.09 µCi) to 270 µl supernatant of lyzed cells. After an 3-h 
incubation, the reaction was stopped by injecting 200 µL 4 N H2SO4 and the mixture 
was kept for one h at room temperature to ensure complete absorption of released CO2 
by the capture reagent (tissue solubilizer NCSII, Amersham). The captured 14CO2 was 
measured by scintillation counting in a Wallac 1450 MicroBeta liquid scintillation 
counter. The protein concentration in the supernatant of lyzed cells was determined by 
the BioRad protein assay kit.   
   In order to measure inhibition in cell extracts of TPA-induced untreated HMC-1 
cells, supernatants of lyzed cells were incubated with the respective compound and 
HDC activity determined as describe above. 
 
 
Molecular modeling 
 
The protein sequence of hHDC (Swiss-Prot access number: P19113) was aligned with 
the sequence of pDDC obtained from the PDB structure (PDB code: 1JS3; (8)), and 
rHDC (Swiss-Prot access number: P16453) with ClustalIW (25). Based on the 
sequence alignment of pDDC and hHDC, the structure of the dimeric hHDC was 
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constructed by superposing two monomeric HDCs, obtained from Swiss-Model 
database (http://swissmodel.expasy.org/), into the crystal structure of dimeric (subunit 
A and B) pDDC by using InsightII (version 2000, Accelrys Corporate, San Diego, 
USA). The structure of phosphopyridoxyl-histidine was constructed into hHDC based 
on the known 3D coordinates of the phosphopyridoxyl-carbiDOPA (PDB code: 1JS3), 
followed by energy minimization performed with the InsightII/Built module (steepest 
descents until a maximum derivative of 20 kcal/mol, CVFF force field). The 
assembled structures consisting of hHDC and phosphopyridoxyl-histidine analog 
were further optimized by energy minimization using InsightII/Discover module 
(conjugation gradient until a maximum derivative of 0.01 kcal/mol, CVFF force 
field). 
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4.4 RESULTS 
 
Coenzyme-substrate analogs as inhibitors of hHDC 
 
To target HDC in mammalian cells, we designed and synthesized potential 
coenzyme-histidine-based precursor inhibitors for hHDC (compounds 1, 2, 3 and 9; 
Fig. 2B), which we assumed to be membrane permeable and phosphorylated by 
intracellular pyridoxal kinase (26, 27). Recently we showed that intracellular ODC 
could be targeted with this kind of transition-state-based inhibitor (20). ODC (half life, 
20 ~ 60 min) and HDC (half life, 1 ~ 2 h) are inducible and short-lived enzymes (12, 
28) and the freshly synthesized apoenzymes will be excellent targets for these 
inhibitors. As the knowledge of the structural prerequisite in the active site 
environment was marginal, we synthesized and tested compounds with variations in 
the substrate moiety (Compound 4 to 8, Fig. 2B).  
To identify effective inhibitors for newly synthesized apo HDC, HMC-1 cells were 
induced with TPA and HDC activities measured after cells have been pre-treated with 
the various compounds (Fig. 2B). Among the 9 tested structural diverse compounds, 
pyridoxyl-histidine methyl ester (PHME, compound 1, Fig. 2B) was found to be the 
most potent inhibitor for HDC in HMC-1 cells and in cell extracts if subjected to 150 
µM pyridoxyl-substrate conjugate. The phosphorylated PHME was also found to be a 
potent inhibitor (IC50 ~ 50 µM) for hHDC when tested in cell extracts of HMC-1, but 
was inactive in cells. All the other analogs did not significantly inhibit HDC in 
HMC-1 cells, although some (compounds 2, 6 and 9) slightly inhibited HDC activity 
in cell extracts (Fig. 2B).  
Non-induced (TPA) HMC-1 cells exhibited already a basal activity, which was 
slightly (15%) affected by 200 µM PHME (Fig. 3). Under these conditions, the 
inhibitor has to compete bound PLP (intracellular concentration, ∼ 20 to 50 µM (29)) 
out of the active site of HDC, which probably is a slow process. After induction 
(black columns,  
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Fig. 3), freshly synthesized apoenzyme, indicated by a 2.5-fold increase in enzyme 
activity, is the main target of the inhibitor in the cells. This fraction is inhibited to ~ 
60%, comparable to the inhibition caused by HME (Fig. 2A) in vitro. Furthermore, 
PHME specifically inhibited hHDC in cells without affecting the activity of human 
ornithine decarboxylase and cell viability (unpublished observation). 
 
 
Figure 3.  PHME inhibition of TPA-induced HDC activity in HMC-1 cells. HMC-1 
cells were treated with or without PHME for 3 h followed by an 3-h incubation with 
or without TPA (100 nM). Cells were collected, lyzed and HDC activities measured as 
described in the legend of Fig. 2. The results are listed as the average ± stdev (n=3). 
 
 
Modeling the active site of hHDC 
 
In order to understand the structure-activity relationship of the synthesized 
compounds (Fig. 2B) and the active site of HDC, we built up by molecular modeling 
the active site of HDC together with the presumed intracellularly active form of 
PHME (phosphorylated and deesterified compound 1, Fig. 2B). The crystal structure 
of pig DDC (51% sequence identity with mammalian HDC, Fig. 4) served as template 
for constructing dimeric hHDC. Residues of hHDC and pDDC as well as rat HDC 
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surrounding the coenzyme-substrate analog within a distance of 4-5 Å were listed in 
Table 1, aligned as previously reported (6), and shown in Fig. 4. Most residues in the 
active site of pDDC and hHDC are identical (71%), except the seven conservative, 
semi-conservative or non-conservative substitutions (Ile101 (pDDC) → Leu102 
(hHDC), Gly354 (pDDC) → Ser354 (hHDC), Phe80 (pDDC) → Tyr81 (hHDC), 
Thr82 (pDDC) → Ala83 (hHDC), Ser147 (pDDC) → Thr149 (hHDC), Ala148 
(pDDC) → Val150 (hHDC) and His302 (pDDC) → Ser304 (hHDC)) shown in Fig. 
5C and Table 1. Among them, Ala83 and Ser304 have been shown to be important 
residues for maintaining the activity of mouse HDC (6).  
   In the active site of hHDC, the imidazole ring was located in a pocket composed 
by residues Tyr81B, Asn302B, Ser304B, Lys305B, Leu102A, Phe104A and Ser354A 
(Fig. 5A), whereas in pig DDC, the aromatic ring is surrounded by residues PheB80, 
AsnB300, HisB302, LysB303, IleA101, PheA103 and GlyA354 (Fig. 5B).   
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Figure 4. Sequence alignment of human HDC, rat HDC and pig DDC. The protein 
sequence of hHDC (Swiss-Prot access number: P19113) was aligned with the 
sequence of pDDC obtained from the PDB structure (PDB code: 1JS3 (8)), and rHDC 
(Swiss-Prot access number: P16453) with ClustalIW (25). * = identical residues in all 
sequences in the alignment; : = conserved substitutions; . = semi-conserved 
substitutions. Arrows indicate the non-identical residues of active sites (see Table 1 
and Fig. 5C). 
  
 
 
Table 1. Comparison of residues in the active site of pDDC, hHDC and rHDC.  
Residues indicated by italic fonts are the non-identical substitutions. Bold residues are 
the non-conservative substitutions. * = identical residues; : = conserved substitutions;  
. = semi-conserved substitutions. 
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Figure 5. Active site model of hHDC and pDDC, containing a coenzyme-substrate 
analog. A) The modeled active site of hHDC (green) and the 
phosphopyridoxyl-histidine conjugate (pink-yellow). B) The active site of pDDC 
together with the phosphopyridoxyl-carbiDOPA (pink-brown) (PDB code: 1JS3). C) 
Superposed stereo view of the of non-identical residues of the active site of hHDC 
(red, the side chains are labeled with white fonts) and pDDC (blue, labels in cyan) 
together with phosphopyridoxyl (pink)-histidine (yellow) and phosphopyridoxyl 
(pink)-carbiDOPA (brown) conjugates. Residues surrounding the coenzyme-substrate 
analog within a distance of 4-5 Å are indicated.  
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4.5 DISCUSSION 
 
Exploring the steric constraints in the binding-site by attaching additional groups on 
the mimic of a reaction intermediate is a robust methodology in understanding the 
structural requirements of the active site and in developing inhibitors (20, 30). The 
present study describes the successful action of PHME, a newly developed inhibitor 
of this kind of intracellular hHDC. The development strategy was based on the 
external aldimine, an obligatory intermediate in the mechanism of action of hHDC. In 
the tested 9 pyridoxyl derivatives, the 5’-phosphate group is eliminated and the 
carboxyl group is esterified with methanol. The rationale behind the design was that 
these compound have no negative net charge and very likely cross the cell membrane 
as it was reported for several pyridoxyl-amines (27, 31), a pyridoxyl-methionine 
analog (32) and compound 7 (20). The methyl ester group in the compounds will be 
hydrolysed by endogenous esterase (10), and the resulting inhibitors, after being 
phosphorylated by intracellular pyridoxal kinase (26, 31), will bind the cellular newly 
synthesized apo HDC with a high affinity. 
Here, we tested several structural diverse mimics of a reaction intermediate of 
HDC (ES-PLP, Fig. 1) with variations in the substrate motif (Fig. 2). Only PHME 
showed remarkable inhibition both in cell extract and in cells, which already indicated 
that the binding site of hHDC is rather specific and seems not to accept variations in 
the substrate moiety. 
   To understand the structural basis of the binding specificity of hHDC, a model 
consisting of dimeric hHDC and phosphopyridoxyl-histidine, the cellular active from 
of PHME, was constructed by homologous modeling methods. With this model, the 
substrate specificity of these two proteins can be explained by the substitutions 
Gly354 (pDDC) → Ser354 (hHDC), Phe80 (pDDC) → Tyr81 (hHDC) and His302 
(pDDC) → Ser304 (hHDC) (Fig. 5A-C and Table 1). The imidazole side chain of the 
substrate is in a favorite position to form hydrogen bonds with the hydroxyl groups of 
Tyr81, Ser304 or Ser354 of hHDC, whereas the hydroxyl groups of carbiDOPA are 
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favorably interacting with the imidazole ring of His302 of pDDC as reported (6, 33). 
Mutation of Ser304 of hHDC to Gly decreased the enzymic activity but not 
completely (6) indicating Ser304 participates in substrate binding rather than in the 
catalytic conversion as also suggested by the present model. This binding mode of the 
coenzyme-substrate conjugate in the active site of hHDC demonstrates that the 
imidazole binding moiety of substrate consists of a tightly packed and specific pocket 
in contrast to that of pDDC (Fig. 5A-C, (34)). Tyr81B in hHDC adopted a ‘closed 
conformation’ in contrast to the ‘open conformation’ of the corresponding residue 
Phe80B in pDDC and can form a stacking interaction with the imidazole ring and an 
additional hydrogen bond with the N1 atom of the imidazole ring (Fig. 5C).  This 
different conformation forms a small but specific binding pocket for the imidazole 
ring of the substrate histidine, which cannot accept bigger ligands like pDDC (Fig. 
5C). The model displays also a more tightly packing in hHDC than in pDDC of active 
site residues surrounding the phosphate group (Fig. 5A-C). 
   The small but specific binding site of hHDC as analyzed above explains why the 
conjugates with a larger amino acid moiety (His(1-Me), 2; Phe, 4; 
ß-(3-Pyridyl)-D-Ala, 5; Trp, 6; tert-butoxycarbonyl (BOC) protected ornithine, 7 and 
BOC protected α,γ-diaminobutyric acid, 8; Fig. 2B) do not significantly inhibit 
hHDC in cells. Compound 2, which has an additional methyl group at the imidazole 
ring, showed already much less inhibition than compound 1 (Fig. 2). The model 
indicates that the methyl group at N1 of the imidazole ring disturbs the formation of a 
hydrogen bond to Tyr81B, Ser304B or Ser354A in the active site of hHDC and exerts 
steric constraints (Fig. 2B, 5A and 5C). The failure of inhibition by compound 3 and 
9 (cyclized form of 3) is mostly likely due to the missing carboxylate group, which 
could interact with the conservative positively charged Arg 447B during catalysis (Fig. 
2 and 5A).  
   Besides the structure-activity relationship gained from the designed compounds, 
the proposed model reasonably explains previous experimental data. The hHDC 
model points out that hHDC contains a narrow side chain-binding pocket and a 
relatively large binding site for the carboxylate group. Additional modifications on 
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histidine, such as α- and ß- substitutions (9) as well as substitutions at the imidazole 
ring (10), will decrease the binding affinity due to steric hindrance in this region. The 
small binding site does not accept a bulky fragment such as α-methyl dopa either (Fig. 
5C), which is a potent inhibitor for DDC but not for rHDC (35).  The relatively large 
free binding region around the carboxylate group in hHDC (Fig. 5A) could accept 
additional moieties, whereas in DDC this is not the case (Fig. 5B). Indeed, PHME, 
phosphopyridoxyl-histidine methyl ester (see above), HME (10), the dipeptide 
His-Phe (13, 36) as well as others (37) inhibited mammalian HDC in vitro. This fact 
could be utilized to develop more potent inhibitors for hHDC by modifications at the 
carboxylate group. 
 
   In conclusion, the present investigation with pyridoxyl-histidine analogs as 
possible precursor ligands for hHDC revealed a novel intracellular inhibitor of hHDC 
and a structural model of its active site containing not only the coenzyme but also 
substrate analogs. These findings can serve as structural basis for functional studies of 
HDC and to develop more potent inhibitors for this enzyme of pharmaceutical 
interest.  
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5. Appendix 
 
 
The nanoelectrospray mass spectra of phosphopyridoxyl-tryptophan methyl 
ester (pPTME). 
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The nanoelectrospray mass spectra of pyridoxyl-tryptophan methyl ester 
(PTME).  
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The nanoelectrospray mass spectra of pyridoxyl-ornithine (BOC) methyl ester 
(POB).  
 
 
 
 
 
 
 
 
Appendix                                                           109 
  
 
 
 
The nanoelectrospray mass spectra of pyridoxyl-histidine methyl ester (PHME).  
 
 
 
 
 
 
 
 
 
 
 110
Acknowledgements 
 
Here, I would like to thank many people who help me during my PhD study.  
 
Prof. Heinz Gehring, my supervisor, who gives me the opportunity to work in his group, 
provides such dynamic and interdisciplinary projects and initiates fruitful collaborations.  
 
Prof. Philipp Christen, who generously shares his ideas, knowledge and experience, and 
reviewed my dissertation. 
 
Prof. Peter Sonderegger, who supervises my PhD dissertation as the responsible faculty 
member.  
 
Prof. Stefan Bienz, who gives me the opportunity to work in his laboratory and provides 
the excellent organic chemistry facilities. 
 
Margrit, Mathys Würfl who helps me a lot in preparing the dissertation and 
administrative issues. 
 
Doris Grossenbacher, Christine Lüthi, Rahel Siegenthaler, Wanjiang Han, Rouzanna 
Zakaryan, Lilian Quero, Steffen Pahlich and Karim Bschir for their collaborations and 
technical assistance.  
 
Maurizio Campagna, Pascal Bisegger, Michael Méret and Xinjun Luan for their 
substantive help in organic synthesis and analytical methods.  
 
My wife, Jing, who gives me great support not only in daily life but also in bioscience.  
 
My friends Hu Guoquan, Zhou Yueyang, Reto Kreuzer, Huang Zhixin, Lu Jianjun, Chen 
Shangjun, Liu Huanfa, Xue Gongda, Yang Zhou, Liu Junguo, Huang Danzhi, Tao Minli,  
Liu Peng, Zhou Ting and Wei Ren for their kind help and having fun together.  
 
All my colleagues in University Zurich, for their valuable and generous help.  
 111
WU Fang 
born on June 2nd, 1976 in Xi’an, China 
Nationality: China 
      
1992- 1995         Qing An High School, Xi’an, Shannxi, China 
 
1995- 1999         Department of biochemistry  
Shanghai Jiao Tong University, Shanghai, China. 
      B.Sc, Major in Biochemistry. 
Bachelor thesis: Study on the production of PUFAs in the P.  
tricornutum 
 
 
1999- 2002         Shanghai Research Centre of Biotechnology  
                                    Shanghai Institutes for Biological Sciences 
Chinese Academy of Science. 
                                    M.Sc in biochemistry and molecular biology  
Master thesis: Design and study the biomimic ligands for the human  
tissue plasminogen activator 
 
2002- 2003       Pre-clinical Safety, Novartis Pharma, Basel, Switzerland. 
  
2003- 2007     Department of Biochemistry 
University Zürich, Switzerland. 
                                    PhD student, supported by COST Switzerland, Action 922 
                                    Supervised by Prof. Dr. Heinz Gehring 
                        Dissertation: Design, synthesis and characterization of coenzyme-    
substrate inhibitors targeting intracellular pyridoxal 5’-phosphate-
dependent enzymes 
 
 
 
 
. 
 
 
